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ABSTRACT

Aberrant epigenetic alterations in the genome are believed to be a potential
cause of some forms of cancer. Due to their reversibility, epigenetic modifications are
considered potentially useful in drug development (epi-drugs). Currently available
synthetic epi-drugs have many adverse effects. Epigenetic pathways may represent
targets for natural product utilized in cancer treatment. The present study was designed
to evaluate the efficacy of a traditionally used product, wild yam root extract (WYRE), as
a potential demethylating agent in breast cancer. Two breast cancer cell lines were
used, MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (ER negative, ER-),
and the effect of WYRE on a gene, GATA3, a potential marker of breast cancer
development was studied. GATA3 expression is controlled by methylation, and it is
found to be expressed higher in ER+ cells with correlating promoter hypomethylation,
and

its

expression

is

insignificant

in

ER-

cells

correlating

with

promoter

hypermethylation. In the current study, cells were treated with WYRE (0-50 μg/mL) for
72h and then evaluated for changes in mRNA and in promoter methylation patterns.
WYRE significantly reduced cell proliferation of both cell lines and increased
transcription of GATA3 and methylating DNMT proteins (DNMT1, 3A, and 3B) in a
concentration-dependent manner. Global DNA methylation as analyzed by 5'-methyl-2'deoxycytidine (5-mC) and 5-hydroxymethylcytosine (5-hmC) showed that 5-mC was
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increased in MCF-7, whereas 5-hmC level was reduced in MDA-MB-231 cells. Since 5hmC is generated from 5-mC by ten-eleven-translocation (TET) enzymes, their
expression was examined as well following WYRE treatment. Of the TET proteins only
TET3 mRNA expression was increased by WYRE (50 μg/mL) in MDA-MB-231 cells; no
changes were noted in MCF-7 cells. Methylation analysis of the GATA3 promoter
indicated demethylating activity of WYRE in MDA-MB-231 cells. Two compound isolates
from WYRE considered responsible for the anti-cancer activity, dioscin and diosgenin,
were also evaluated as described above for the root extract. Both dioscin and diosgenin
were able to reduce in vitro cell viability of both ER+ (MCF-7) and ER (MDA-MB-231)
human breast cancer cells, with dioscin demonstrating greater potentcy than diosgenin
in both cell lines. Dioscin at 5.76 µM showed upregulation of GATA3 mRNA expression
in MDA-MB-231 cell only. GATA3 protein expression was also enhanced in a
concentration- dependent manner in MDA-MB-231 cells treated with dioscin (0-5.76 µM)
as seen by both western blot, and by immunocytochemistry followed by confocal
microscopy. Interestingly, dioscin was founded to enhance the expression of GATA3
protein in both cell lines. Despite increased transcription in the MDA-MB-231 cells, an
upstream (ZFPM2) and downstream (E-cadherin) markers of GATA3 function were
examined. ZFPM2 mRNA expression significantly increased by dioscin at 5.76 µM in
both cell lines, as did E-cadherin expression. Other cell transition markers were studied,
such as MMP9 and VIM. We found that dioscin at 2.30 µM decreased expression of
MMP9 transcription, and at 2.30 and 5.76 µM suppressed VIM mRNA expression in
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MDA-MB-231 cells. Notably, dioscin was found to have an inhibitory effect on migration
of MDA-MB-231 cells in concentration- and time- dependent manner, as observed by a
wound-healing assay and in migration/invasion assay in both breast cancer cell lines.
These findings reveal a new therapeutic potential for anti-metastatic therapy targeting
epigenome and in the future these plant extract as a whole or dioscin may be able to
offer an efficacious adjuvant therapy to women with breast cancer.
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CHAPTER 1.
INTRODUCTION

Breast cancer

Breast cancer accounts for ∼30% of all cancers diagnosed in the United States,
and it is the second leading cause of cancer death in women (Ordway et al. 2007,
Society 2014). Overall, women have a >10% lifetime risk of developing invasive breast
cancer and the risk increase with age; breast cancer accounts for 1% of all male
cancers (Feuer et al. 1993, Lin et al. 2010). Mammary gland development initiates
during fetal development and continues postnatally through puberty, pregnancy,
lactation, and subsequent involution during which the gland undergoes extensive
morphological and functional changes (Muller et al. 2006). The development of cancer
in the breast is a stepwise process that begins in mammary ducts and progress through
five stages (0-4). The American Joint Committee on Cancer (AJCC) has designated
staging based on tumor size, the degree of lymph node involvement, the presence of
inflammatory signs, and evidence of metastasis. Stage 0 is used to describe noninvasive breast cancers, such as DCIS (ductal carcinoma in situ) where there all
evidence of cancer cells or non-cancerous abnormal cells is locally contained. Stage 1,
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tumors are less than 2 cm, noninvasive, and growth of the cells does not affect the
functions of neighboring cells and tissues. Stage 2, the tumor size is between 2 and 5
cm and becomes invasive and begins to affect axillary nodes but does not reach any
neighboring tissues. Stage 3, tumor cells in the individual lymph nodes begin clumping
together and cause inflammation. The tumor size is greater than 5 cm or axillary lymph
node fixed to each other or other structures. The fourth stage breast cancer
metastasizes to other distant organs most often the brain, lung, or liver. (Agrawal et al.
2006, Institution)
There are many risk factors proposed for breast cancer development that include
individual genetic background, pregnancy, and lifestyle elements, such as diet and
environment. Although extensive research has been done, the causes and mechanisms
of breast cancer development and progression are complex and still remain
inconclusive (Cebrian et al. 2006, Veeck and Esteller 2010). Estrogen both from
endogenous and exogenous sources and their receptors have a proliferative effect on
mammary gland epithelium; estrogens may increase susceptibility to environmental
carcinogens, oxidative catabolism of estrogens generate reactive oxygen species (ROS)
that cause genetic damage. Mutations of BRCA1 and BRCA2 and other related genes
such as p53, Bcl-2, Her2, or c-Myc can be significant for breast cancer development
(McCance et al. 2010). Breast carcinogenesis involves not only uncontrolled
proliferation, but also alterations in cell signaling pathways as well as aberrant or loss of
apoptosis as a consequence of accumulated genetic alteration (McCance et al. 2010).
Even though the mechanisms associated with breast cancer are genetic alterations,
including specific gene amplifications, deletions, point mutations, chromosome
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rearrangements, and aneuploidy like other types of cancers, it is also driven by
epigenetic mechanisms. (Dworkin, Huang, and Toland 2009a, Lo and Sukumar 2008,
Jovanovic et al. 2010, Kress et al. 2010)

Epigenetics

The term epigenetics is deﬁned as heritable changes in gene expression that do
not involve DNA nucleotide sequences (Jones and Laird 1999, Yoo and Jones 2006). It
is the “stable alterations in gene expression potential that arise during development and
proliferation” (Jaenisch and Bird 2003). Furthermore, epigenetics is also deﬁned as “the
manifestation of a phenotype, which can be transmitted to the next generation of cells or
individuals, without alteration of the DNA sequence (genotype)” (Devinoy and Rijnkels
2010). In general, epigenetics has been interpreted more widely to include any external
effect on the phenotype. Epigenetic therapy is a new and rapidly developing area and a
potentially useful form of therapy in breast cancer

due to the fact that epigenetic

defects mostly occur at the chromosomal level in transformed cells and are thought to
be more easily reversible in comparison with genetic defects (Kristensen, Nielsen, and
Hansen 2009). At the biochemical level, the epigenetic alteration in chromatin
conformation involves DNA methylation, several forms of histone modifications, and
microRNA (miRNA) expression. These events modulate chromatin structure and in turn
activate or silence gene expression (Lo and Sukumar 2008, Lustberg and Ramaswamy
2009). The understanding of these epigenetic changes and their contributions to
carcinogenesis is very important for further progress in the field of diagnosis, prognosis,
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and therapy of any cancer including breast cancer.

Epigenetic Mechanisms

1. Histone Modification

One of the epigenetic mechanisms influencing gene transcription is histone
modification. Histone proteins are responsible for maintaining chromatin structure either
in an accessible or inaccessible state to various transcriptional activators and
repressors for their binding to gene promoters (Dhalluin et al. 1999). The nucleosomes
of euchromatic DNA contain an octamer of four core histones (H2A, H2B, H3, and H4)
around which 146 bp of DNA are wrapped (Davis and Ross 2007, Ito and Adcock 2002,
Luger et al. 1997, Minard, Jain, and Barton 2009, Strahl and Allis 2000). Histones can
be

modified

post-translationally

by

acetylation,

methylation,

phosphorylation,

sumoylation, ubiquitination, ADP ribosylation, deamination, proline isomerization, and
newly identified propionylation (Liu et al. 2009, Schubeler et al. 2004, Shilatifard 2006)
and all these effects can alter the accessibility of DNA to transcriptional activity. Most of
these modifications are reversible (Davis and Ross 2007). Moreover, gene repression or
activation by histone acetylation or methylation is dependent on the specific residues.
The most important histone modifications, having effects on gene expression, are
located on histone H3 and histone H4 (Bronner et al. 2010). One of them, known to
have a gene silencing role and to have a strong relationship with DNA methylation, is
the di or trimethylation of lysine 9 of histone 3 (H3K9me2 or H3K9me3). But methylation
on the same histone on lysine 4 (H3K4me) is related to gene activation. All these
4

modifications are catalyzed by specific enzymes (Peterson and Laniel 2004, Sims and
Reinberg 2006, Lo and Sukumar 2008).

Acetylation of histones occurs within the

amino-terminal tails protruding from the surface of the nucleosomes and also on the
globular core region by transfer of acetyl group from acetyl-CoA to the ε amino group of
lysine residues (Nε). The reaction is catalyzed by histone acetyl transferase (HAT). The
global acetylation of histone tails decreases electrostatic interactions between the
negatively charged DNA and the basic lysine residues (Travers and Thompson 2004).
As a result, the chromatin becomes more open to provide access for transcription
factors to DNA. Conversely, deacetylation, which is catalyzed by histone deacetylases
(HDACs), removes the neutralizing acetyl charge and induces chromatin condensation
and gene inactivation and silencing (Figure 1) (Kouzarides 2007).
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Figure

1:

Schematic

representation

of

histone

modification

(acetylation

and

deacetylation). HATs induce relaxed chromatin which allows access to the various
transcriptional factors associated with gene activation (gene switched on). HDACs
induce closed chromatin associated with gene repression (gene switched off). HAT=
histone acetyltransferase; HDAC= histone deacetylases; AC acetylation. (Khan et al.
2012)
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Moreover, HATs also acetylate several nonhistone proteins such as GATA1, E2F1, pRB,
or TP53 frequently associated with cellular transformation (Martinez-Balbas et al. 2000).
HATs cannot bind to target gene promoters directly but rather are recruited by DNAbound transcription factors (Roth, Denu, and Allis 2001). However, HDACs whose
primary role is to oppose the activity of HATs are recruited to the hypermethylated CpG
islands of tumor suppressor genes via Methyl-CpG-binding Domain (MBDs) or
independently of methylation by specific transcription factors (Deckert and Struhl 2001).
Many nonhistone proteins are also used as substrates for HDACs (Deckert and Struhl
2001, Gray and Ekstrom 2001, McLaughlin and La Thangue 2004, Robertson et al.
2000). HATs can be classified into five families: the GNAT family, the MYST family, the
p300/CBP family, the SRC family, and the TAFII250 family (Suzuki and Miyata 2006,
Roth, Denu, and Allis 2001). Until now, 18 human HDACs have been identified and are
grouped into four classes, Classes I, II, III, and IV, based on their homology with yeast
HDACs and their phylogenetic conservation (Gregoretti, Lee, and Goodson 2004).
Histone methylation occurs in lysine and arginine residues, catalyzed by histone lysine
methyl transferases (lysine) or histone arginine methyl transferases (arginie) (Yamane
et al. 2007). At present, there are 24 known sites of methylation of histones: 17 are
lysine residues, and 7 are arginine residues (Bannister and Kouzarides 2005).
Furthermore, lysine side chains may be mono-, di-, or trimethylated, whereas the
arginine side chain may be either mono- or dimethylated. In contrast to histone
acetylation, histone methylation does not change histone’s charge (Dalvai and Bystricky
2010). Recruitment of specific motif bearing factors to the methylated lysine is
responsible for affecting chromatin structure. Histone demethylation is catalyzed by
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histone demethylases (Shi et al. 2004, Tsukada et al. 2006). Thus, HAT and HDAC
inhibitors could potentially represent new treatment options for cancer (Jovanovic et al.
2010, Sung et al. 2008, Eliseeva et al. 2007).

Impact of bioactive dietary components on histone modification
Considerable attention has been paid to bioactive dietary components as breast
cancer preventive agents targeting HAT and HDAC activities. Although direct cancer
prevention by specific modulators of HAT has not yet been demonstrated (Hauser and
Jung 2008), several natural products, such as anacardic acid found in cashew
(Anacardium occidentale), garcinol, a polyisoprenylated benzophenone derivative from
Garcinia indica, and curcumin from turmeric, have the potential to inhibit p300 and
p300/CBP associated factor (PCAF) activity (Fu and Kurzrock 2010, Balasubramanyam
et al. 2003, Balasubramanyam et al. 2004, Varier et al. 2004). EGCG has shown to
specifically inhibit HAT but not HDAC in B lymphocytes (Choi et al. 2009). Sallylmercaptocysteine, a compound found in garlic (Allium sativum), is able to induce
histone acetylation in T47D human breast cancer cells (Lea et al. 2002).

Further

studies are necessary to evaluate the potency of these bioactive dietary compounds as
HAT inhibitors in breast cancer models. Currently, a large number of structurally diverse
HDAC inhibitors have been synthetically developed or purified from natural sources (Lo
and Sukumar 2008, Meeran, Ahmed, and Tollefsbol 2010). Among them suberoylanilide
hydroxamic acid (SAHA or vorinostat) has been approved for treatment of cutaneous Tcell lymphomas (Mai and Altucci 2009, Marks 2007). HDAC inhibitors are classified into
four main groups: hydroxamic acids, cyclic peptides, aliphatic acids, and benzamides
8

(Dalvai and Bystricky 2010, Gregoretti, Lee, and Goodson 2004). Moreover, it was also
shown that the HDAC inhibitors played different roles in ER+ and ER- breast cancer
cells (Thomas and Munster 2009). The tea polyphenol EGCG, when applied to MCF-7
cells (ER+), can decrease hTERT promoter methylation and ablate histone H3Lys9
acetylation (Berletch et al. 2008). In MDA-MB-231 cells (ER-), EGCG together with
trichostatin A (TSA) can reactivate ERα expression via remodeling of the chromatin
structure of the ERα promoter by altering the status of histone acetylation and
methylation. A decrease in binding of the transcription repressor complex, Rb/p130-E2F
4/5-HDAC1- SUV39H1-DNMT1, into the regulatory region of ERα promoter by EGCG
and TSA was also observed (Li et al. 2010). Sulforaphane (SFN) is an isothiocyanate,
derived from glucoraphanin in broccoli and broccoli sprouts (Meeran, Ahmed, and
Tollefsbol 2010). Like other isothiocyanates, SFN is metabolized via the mercapturic
pathway (Nian et al. 2009). A phase I trial of broccoli sprout extracts containing
glucosinolates and isothiocyanates produced no adverse effects on human volunteers
(Shapiro et al. 2006). Computer modeling predicted that SFN-cysteine (SFN-Cys) was a
good fit for the HDAC active site (Nian et al. 2009). Further studies indicate that SFN is
able to inhibit HDAC activity in human breast cancer cell lines (MDA-MB-231, MDA-MB468, MCF-7, and T47D) without altering the acetylation of H3 or H4 (Pledgie-Tracy,
Sobolewski, and Davidson 2007). In another study, it was documented that SFN
inhibited HDAC activity in MCF-7 and MDA-MB-231 human breast cancer cells and
increased the level of active chromatin markers such as acetyl-H3, acetyl-H3K9, and
acetyl-H4, whereas it decreased the inactive chromatin markers like trimethyl-H3K9 and
trimethyl-H3K27 and remodeled the chromatin structure of hTERT promoter (Meeran,
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Ahmed, and Tollefsbol 2010). However, EGCG and pEGCG decreased the level of
acetyl H3, acetyl- H3K9, and acetyl-H4 to the hTERT promoter in MCF-7 and MDA-MB231 cells (Meeran et al. 2011). Genistein inactivated histone trimethyl- H3K9 followed by
transcriptional repression of hTERT in human breast cancer cells (Li et al. 2009). Longterm genistein treatment (40-60 days) inhibited the growth of MCF-7 cells and markedly
reduced the basal expression of acetylated histone 3 (H3) (Jawaid et al. 2010). SAllylmercaptocysteine, a metabolite of diallyl disulfide, which is found in garlic and other
Allium species, has been shown to induce histone acetylation in T47D human breast
cancer cells (Lea et al. 2002). Resveratrol, a phytoalexin from grape, inhibited the
growth of BRCA 1 mutant tumor cells by upregulating SIRT1 (the mammalian
homologue of yeast sir2 belongs to type III HDAC) (Wang et al. 2008). Treatment of
breast cancer cells with resveratrol induces SIRT1 (a member of the sirtuin protein
family of NAD+-dependent deacetylase) deacetylase activity, which promotes SIRT1
association with p300 (an HAT) and down-regulates p300 transferase activity that
impairs the β-catenin and NFkB-p65 signaling cascades in MCF-7cells (Bourguignon,
Xia, and Wong 2009). Also, twelve dietary polyphenols evaluated in MCF-7 cells for
DNA methylation and gene activation analysis by Paluszczak et al. were unable to alter
the global methylation pattern of histone H3 (Paluszczak, Krajka-Kuzniak, and BaerDubowska 2010).
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2. micro RNA

The most recently emerged participant in the epigenetic field is a family of small
regulatory RNAs called microRNAs (miRNA), which are small noncoding RNAs ranging
in size from 19 to 24 nucleotides that inhibit protein expression of target genes (Lewis,
Burge, and Bartel 2005). These RNAs regulate the expression of target genes by
sequence specific binding to the 3’-untranslated region (3’UTR) of target mRNAs,
resulting in either mRNA degradation or inhibition of mRNA translation (He and Hannon
2004). miRNA can directly or indirectly regulate cancer progression either by acting as
the tumor suppressor or by altering epigenetic modifying enzymes (Meeran, Ahmed,
and Tollefsbol 2010). Extensive analyses of genomic sequences of miRNA genes have
shown that approximately half of them are associated with CpG islands (Weber et al.
2007, Lehmann et al. 2008). Current bioinformatics tools predict that each miRNA
recognizes an average of 100-200 different mRNA targets (Lewis, Burge, and Bartel
2005). Epigenetic silencing of miRNA may be a reflection of tissue specificity. Up
regulation of miR-205 is seen in lung, bladder, and pancreatic cancers; however, downregulation is seen in prostate, breast, and esophageal squamous cell carcinoma (Melo
and Esteller 2011). Most importantly, expression patterns of miRNAs were correlated
with tumor stage, proliferation index, estrogen and progesterone receptor expression,
and vascular invasion (Iorio et al. 2005). Therefore, miRNAs can be used as a
biomarker of cancer progression and development.
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In breast cancer, epigenetic silencing of several miRNAs is a frequent and early
event (Veeck and Esteller 2010, Lehmann et al. 2008, Chuang and Jones 2007). Many
of the miRNAs including miR-126, miR- 9-1, miR-10b, miR- 125b,miR-145, miR-21, and
miR-155 are reported to be deregulated in breast cancer (Iorio et al. 2005, Lehmann et
al. 2008, Si et al. 2007). The differentiation program of epithelial to mesenchymal
transition (EMT) involves changes in a number of miRNAs. Some of these miRNAs
have been shown to control cellular plasticity through the suppression of genes involved
in defining the epithelial and mesenchymal cell states (Zeisberg and Neilson 2009).

Impact of bioactive dietary components on miRNA
Although miRNAs are sensitive to chemical compounds, including the DNAdemethylating agent 5-AZA, studies with bioactive dietary components and their role in
miRNA expression and functions in breast cancer are very scarce. One study showed
that expression of miR-15a and miR-16 was upregulated in curcumin-treated MCF-7
cells and that upregulation can reduce the expression of Bcl-2 (Yang et al. 2010). In
other breast cancer cell lines such as SKBR-3 and Bcap-37, curcumin was also able to
increase the expression of miR-15a and miR-16 (Yang et al. 2010).
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3. DNA Methylation, DNA Methyltransferases and Ten Eleven Translocation family
of enyzymes

In mammals, DNA methylation is the most widely studied epigenetic modification
which results in the addition of a methyl group to the carbon-5 (C5) position in the
pyrimidine ring of cytosine located in the context of cytosine-phosphate-guanine (CpG)
dinucleotide of the genomic DNA (Dworkin, Huang, and Toland 2009b). The reaction is
catalyzed by the enzyme DNA methyltransferase (DNMT) with S-adenosyl-methionine
(SAM) as the methyl donor (Suzuki and Miyata 2006) (Figure 2).

Figure 2: Schematic illustration of the enzymatic DNA methylation catalyzed by DNMTs
using SAM as the methyl donor. After the donation of the methyl group (CH 3) SAM is
converted to SAH. SAM= S-adenosyl-L-methionine, SAH= S-adenosyl-homocysteine.
(Khan et al. 2012)
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The number of genes that has been identified to be aberrantly methylated in
breast cancer is rapidly growing. Studies indicate that in breast cancer, epigenetic
alterations such as promoter hypermethylation and gene silencing occur in many genes
participating in apoptosis (HOXA5, RASSF1A, TWIST1), DNA repair (BRCA1),
metabolic events (GSTP1), tissue invasion, and metastatic processes (CDH1, CDH13)
(Widschwendter and Jones 2002, Fackler et al. 2004, Pathiraja, Stearns, and
Oesterreich 2010, Yan et al. 2001). These genes are not only hypermethylated in tumor
cells but also showed increased epigenetic silencing in normal epithelium surrounding
the tumor site, which is similar to cancerization (Ushijima 2007). A recent study
identified 149 genes that are differentially expressed in ER+ versus ER- cells,
differentially methylated on one or more promoter-proximal CpG islands, and exhibit an
inverse correlation between CpG island methylation and mRNA abundance (Sun,
Asmann, et al. 2011). Moreover, many genes identified in breast cancer tissues which
have hypermethylated CpG islands are located near the consensus sequences of the
transcription factor binding sites(Radpour R et al. 2009) indicates further that in breast
cancer the gene expression is also regulated by epigenetic mechanisms.
In mammals, so far five members of the DNMT protein family have been
discovered (DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L) of which only three
were shown to possess catalytic methyltransferase activity (DNMT1, DNMT3A, and
DNMT3B) (Meeran, Ahmed, and Tollefsbol 2010, Lo and Sukumar 2008, Veeck and
Esteller 2010). The mammalian DNMTs consist of two parts: the catalytic C-terminal
domain, which is highly conserved among prokaryotes and eukaryotes, consists of 500
amino acids, and involved in cofactor binding and catalysis; and the regulatory N-
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terminal part consisting of 621 amino acids, required for discrimination between hemi
methylated and unmethylated DNA and not essential for enzyme activities. The most
abundant DNMT is DNMT1, which is a maintenance methyltransferase, positioned at
the replication fork and maintains the methylation pattern during DNA replication.
Human DNMT1 is located on chromosome 19p13.2 and consists of 1616 amino acids.
The DNMT2 is the smallest among the DNMTs (391 amino acids), comprises mainly the
C-terminal domain, and has no regulatory N-terminal domain. This enzyme participates
in the recognition of DNA damage, DNA recombination, and mutation repair (Okano et
al. 1999). Moreover, it was also shown to methylate tRNAAsp (Rai et al. 2007, Goll et al.
2006) which suggested that the substrate specificity of DNMT2 might be different from
that of other DNMTs. DNMT3A and DNMT3B are de novo methyltransferases
upregulated in aging cells and have a C-terminal catalytic domain similar to that in
DNMT1. The amino acid identity between DNMT3A and DNMT3L is very high, but the
latter (DNMT3L) lacks any catalytic activity due to the absence of conserved catalytic
residues. However, DNMT3L is required for the catalytic activity of both DNMT3A and
DNMT3B. In breast cancer, DNMT3B mRNA was found to be overexpressed (Roll et al.
2008, Girault et al. 2003). The structure of all DNMTs is now available, but the
information on DNMT1 is very limited (Medina-Franco et al. 2011). In breast cancer
patients, the mean level of DNMT1, DNMT3A, and DNMT3B overexpression ranged
from 1.8- to 2.9-fold, and probably, DNMT3B played the predominant role (Veeck and
Esteller 2010).
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The mechanisms by which DNMT methylates cytosine C5 has been studied
extensively (Suzuki and Miyata 2006, Medina-Franco et al. 2011, Chen et al. 1991,
O'Gara et al. 1996). Briefly, DNMT forms a complex with DNA, and the cytosine which
will be methylated flips out of the DNA double helix. The thiol of the cysteine residue in
the active sites of the DNMTs acts as a nucleophile that attacks the 6-position of the
target cytosine to generate a covalent DNA-protein intermediate. The intermediate then
accepts a methyl group of the methyl-donating cofactor SAM to form the 5-methyl
covalent adduct and S-adenosyl-Lhomocysteine (SAH). After methyl transfer, the proton
at the 5 position is attracted by a basic residue in the active site of the enzyme, which is
removed from the 6-position by β-elimination to generate the methylated cytosine and
free enzyme. The 5-methylated cytosine base then flips back into its original position
within the DNA (Medina-Franco et al. 2011, Suzuki and Miyata 2006). DNMTs can also
silence genes by other mechanisms. The formation of a repressive transcription
complex by histone deacetylases (HDACs) and the methyl-CpG binding domain (MBD)
family of proteins at the promoter regions does not require promoter methylation
(Lustberg and Ramaswamy 2009, Mistry et al. 2003). Moreover, DNMT1 through its Nterminus binds to HDAC2 and a DNMT1-associated protein called DMAP1 to form a
complex at the replication fork (Rountree, Bachman, and Baylin 2000). This complex
converts acetylated histones to the deacetylated inactive form and highlights the
interplay between methylation and acetylation processes in epigenetic regulation
(Lustberg and Ramaswamy 2009). DNA methylation of the promoter region of a gene
has been shown to be an important factor in its ability to bind different transcription
factors (Campanero, Armstrong, and Flemington 2000, Perini et al. 2005). CpG
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dinucleotide rich regions located in the 5’-end region of the genes are called CpG
islands (Pavlopoulou and Kossida 2010). In humans, approximately 60% of the genes
have CpG islands (Veeck and Esteller 2010). Methylation of CpG islands is the most
commonly studied epigenetic change in human cancers (Stearns, Zhou, and Davidson
2007).

Most CpG islands are unmethylated in noncancerous cells, which promote

active gene transcription. In cancer cells, CpG islands become hypermethylated,
leading to the inactivation of tumor suppressor genes. For example, wellknown tumor
suppressor genes like p16INK4a, APC, and BRCA1 genes are silenced in breast tumors
due to DNA hypermethylation (Silva et al. 2003, Jin et al. 2001, Birgisdottir et al. 2006).
However, some genes are activated during carcinogenesis due to hypomethylation. In
breast cancer, the overexpression of the γ synuclein gene (SNCG) occurs due to SNCG
promoter hypomethylation (Gupta et al. 2003).
In addition, recent studies reveal that 5-mC can be converted to 5hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC),
respectively by the TET (Ten Eleven Translocation) family of enzymes (Chen et al. 2013,
Tan and Shi 2012, Hashimoto et al. 2012, He et al. 2011, Ito et al. 2011). The key
requirement for the oxidation of 5-mC and 5-hmC is the presence of Fe

2+

and 2-

oxoglutarate. The activation of TET enzymes takes place by electron transfer from the
iron cofactor. Moreover, 5-hmC, 5-fC, and 5-caC have been proposed as a potential
intermediates molecules in active DNA demethylation. 5- caC can be recognized and
cleaved by Thymine- DNA- glycosylase that restore unmethylated cytosine (Dhalluin et
al. 1999, Eliseeva et al. 2007, Iorio et al. 2005, Lehmann et al. 2008). Alternatively,
because 5-hmC is more sensitive than 5-mC to deamination (via activation-induced
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deaminase (AID), in turn it can be converted to cytosine following base-excision repair
(BER) pathway-mediated demethylation. It remains unknown whether there are
decarboxylases or deformylases that can remove the modification directly(Chen et al.
2013, Tan and Shi 2012, Hashimoto et al. 2012, He et al. 2011, Ito et al. 2011 ) so, the
gene expression can be reactivated (Figure 3).

Figure 3: Involvement of TET family proteins in the regulation of DNA methylation and
demethylation. TET family proteins (TET1/2/3) catalyze 5-mC oxidation to 5-hmC. TET
family proteins can also convert 5-mC or 5-hmC further into 5-fC and 5-caC, and the
latter may be recognized and excised by thymine DNA glycosylase (TDG) to generate
cytosine and thereby complete demethylation. Alternatively, because 5-hmC is more
sensitive than 5-mC to deamination (via AID) which in turn can be converted to cytosine
following base-excision repair (BER) pathway-mediated demethylation. It remains
unknown whether there are decarboxylases or deformylases that can remove the
modification directly (Tan and Shi 2012).
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Impact of bioactive dietary components on DNA methylation

There are many bioactive dietary compounds that can modulate methylation
pattern of genes in breast cancer (Li and Tollefsbol 2010, Meeran, Ahmed, and
Tollefsbol 2010). Apigenin in Parsley (Petroselinum), curcumin (1,7-bis (4-hydroxy- 3methoxyphenyl)-1,6-heptadiene-3,5-dione) in turmeric (Curcuma longa), EGCG in green
tea (Camellia sinensis), genistein in soybean (Glycine max), resveratrol (3,40,5trihydroxy-trans- stilbene) in red grapes (Vitis vinifera), sulforaphane (SFN) in
cruciferous vegetables (Brassicacaae), and the caffeic acid and chlorogenic acid as
coffee polyphenols are reported to inhibit DNMT enzyme activity in various
cancer/breast cancer models (Meeran, Ahmed, and Tollefsbol 2010, Lee and Zhu 2006).
Several dietary components such as baicalein, myricetin, protocatechuic acid, phloretin,
sinapic acid, resveratrol, rosmarinic acid, ellagic acid, betanin, cyanidin, and galangin
have been studied for potential effects on the activity and expression of DNMTs in
human breast cancer MCF-7 cell lines (Paluszczak, Krajka-Kuzniak, and BaerDubowska 2010). Among these compounds, betanin was found to be the weakest, and
rosmarinic and ellagic acids were the strongest inhibitor of DNMT enzymes. But the
methylation or the expression of RASSF1A, GSTP1, or HIN1 genes in MCF-7 cells
remained unaltered by these dietary polyphenols. However, decitabine partially
demethylated and reactivated these genes in MCF-7 breast cancer cells (Paluszczak,
Krajka-Kuzniak, and Baer-Dubowska 2010). EGCG can also reduce DNMT enzyme
activities indirectly by reducing S-adenosyl-L-methionine (SAM) and increasing Sadenosyl homocysteine (SAH) and homocysteine levels (Lee, Shim, and Zhu 2005). In
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MCF-7 and MDA-MB-231 breast cancer cell lines, EGCG inhibited DNMT and partially
demethylated retinoic acid receptor β2 (RARβ2), which exists in a hypermethylated
state in these cells (Lee, Shim, and Zhu 2005). A novel pro-drug of EGCG (pEGCG)
and SFN significantly inhibited DNMT activities in MCF-7 and MDA-MB-231 cells and
down-regulated hTERT expression (Meeran, Ahmed, and Tollefsbol 2010, Meeran et al.
2011). DNMT1, DNMT3A, and DNMT3B proteins were downregulated in both MCF-10
AT benign cells and MCF-7 breast cancer cells by genistein (Li et al. 2009). Further,
genistein and lycopene (a carotenoid derived from tomato) partially demethylated the
GSTP1 but not RARβ2 gene in MDA-MB-468 (ER-) human breast cancer cells (KingBatoon, Leszczynska, and Klein 2008). However, an In vivo study indicated that
genistein hypermethylated RARβ2 and CCND2 genes in the intraductal tissue of
premenopausal women (Qin et al. 2009). Resveratrol has been shown to have weaker
DNMT inhibitory activity than other dietary components such as EGCG (Meeran, Ahmed,
and Tollefsbol 2010). It was able to inhibit DNMT1 enzyme activity in ERα expressing
MCF-7 cells significantly but not in MDA-MB-231 cells. Moreover, the promoter
methylation pattern on the RARβ2 gene remained unaltered by resveratrol in both cell
lines (MCF-7 and MDA-MB-231) (Stefanska et al. 2010). Furthermore, in a study with
MCF-7 cells, it was demonstrated that resveratrol is able to prevent epigenetic silencing
of the BRCA1 gene induced by the aromatic hydrocarbon receptor (AHR) (Papoutsis et
al. 2010). Two common coffee polyphenols, caffeic acid and chlorogenic acid, partially
inhibited the methylation of the RARβ promoter in MCF-7 and MDA-MB-468 cells (Lee
and Zhu 2006). The mechanisms of inhibition of the DNMT enzyme activity by these
bioactive compounds in breast cancer models was also studied by many investigators.
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The classical synthetic inhibitor 5-AZA, a cytidine analogue, inhibits the DNMT enzyme
by forming irreversible covalent bonds with DNMT1 and incorporating itself into the
replicating DNA, which induces the degradation of DNMT1(Miyamoto and Ushijima
2005, Schaefer et al. 2009). The non-nucleoside DNA methylation inhibitors (such as
procainamide) demethylate DNA by binding to GC-rich DNA sequences (Zacharias and
Koopman 1990). Bioactive natural products such as quercetin, fisetin, and myricetin
which have catechol structures are readily methylated by SAM in the presence of
catechol O-methyltransferase (COMT), resulting in the conversion of SAM to SAH (Lee
and Zhu 2006, Lee, Shim, and Zhu 2005). By using molecular modeling techniques, it
was demonstrated that EGCG, a nonnucleoside analogue and a competitive inhibitor of
DNMT1, exerts its inhibitory effect by blocking the entry of the key nucleotide cytosine
into its active site by hydrogen bonds and Mg2+ can enhance the reaction (Fang et al.
2003). Other tea polyphenols, such as (-)-epicatechin, (-)-epicatechin-3-gallate, (-)epigallocatechin have also been implicated in DNA methylation inhibition; however, they
are not as potent as EGCG (Li and Tollefsbol 2010). The coffee polyphenols, caffeic
acid and chlorogenic acid, inhibit DNA methylation indirectly (noncompetitive) by
forming SAH, as a consequence of COMT-mediated O-methylation (Lee, Shim, and Zhu
2005). Genistein showed both competitive and noncompetitive inhibition of DNMT
activity (Fang et al. 2005). Molecular docking analysis of the interaction between
curcumin and DNMT1 suggested that curcumin covalently blocks the catalytic thiolate of
C1226 of DNMT1 to exert its inhibitory effect (Liu et al. 2009, Fu and Kurzrock 2010).
The inhibition by curcumin seems to be comparatively lower than that of other bioactive
dietary components such as EGCG and genistein (Fu and Kurzrock 2010, Liu et al.

21

2009, Fang, Chen, and Yang 2007).

Tumor Metastasis

One of the classical hallmarks of cancer is the ability for tumor cells to invade and
metastasize (Hanahan and Weinberg 2011). The metastatic properties of tumor cells
were extensively investigated in the late 1970s and early 1980 by means of
experimental metastasis assays (Weigelt, Peterse, and van 't Veer 2005). For example,
studying the metastatic behavior of cultured B16 melanoma cells that were injected
intravenously into mice showed that cells derived from outgrowths of these cells have a
higher metastatic potential than those derived from original cell line (Fidler 1973). Also,
In vitro clones from the parent B16 culture varied greatly in their ability to produce lung
metastases after intravenous injection into mice (Fidler and Kripke 1977). These
observations led to a metastasis model. The metastases represent the end products of
a multi step cell- biological process termed the invasion-metastasis cascade (Valastyan
and Weinberg 2011) whereby epithelial cells in primary tumors, (1) invade locally
through surrounding extracellular matrix (ECM) and stromal cell layers, (2) intravasate
into the lumina of blood vessels, (3) survive the rigors of transport through the
vasculature, (4) arrest at distant organ sites, (5) extravasate into the parenchyma of
distant tissues, (6) initially survive in these foreign microenvironments in order to form
micrometastases, and (7) reinitiate their proliferative programs at the metastatic sites,
thereby generating macroscopic, clinically detectable neoplastic growths or metastatic
colonization (Valastyan and Weinberg 2011, Friedl and Wolf 2003). Each of metastatic
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stages is driven by the acquisition of genetic and/or epigenetic alterations within tumor
cells and the co-option of nonneoplastic stromal cells (Valastyan and Weinberg 2011). In
addition to remodeling the microenvironment to facilitate metastasis, cancer cells also
turn on embryonic morphogenesis regulators to undergo the epithelial-to- mesenchymal
transition (EMT) and turn off differentiation programs, allowing cancer cells to gain
motility, modify cell adhesion and acquire stem-like properties such as self-renew and
are able to generate the diverse tumor cells (Chou et al. 2013). In contrast to EMT,
differentiation is associated with less aggressive tumors and better prognosis. The
emergence of metastases is responsible for over 90% of cancer patient deaths
(Abdelkarim et al. 2011, Gupta and Massague 2006). Patients with basal-type tumors
lacking estrogen receptor (ER-), progesterone receptor (PR-) and ErbB2- referred to as
basal triple- negative breast cancer (BTNBC) that have a worse prognosis compare to
patients with more differentiated, less metastatic tumor expressing markers of the
luminal lineage including the transcription factors GATA3 and ER (Neve et al. 2006,
Perou et al. 2000, Sorlie et al. 2003).

GATA binding protein 3 (GATA3)

GATA-binding protein 3 (GATA3) is a member of the GATA family of zinc finger
transcription factors (GATA1–GATA6) that binds with high affinity to the consensus DNA
site (T/A-GATA-A/G) (Amatori et al. 2010, Ordway et al. 2007).

GATA3 plays an

essential role in T cell development and the specification of the Th2 subset of T cells.
Additionally, GATA3 performs critical functions outside of the hematopoietic system,
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including a role in the development of epithelial structures of skin, inner ear, central
nervous system, kidney, and importantly for the proposed studies, the mammary gland
(Amatori et al. 2010, Kouros-Mehr et al. 2008, Kouros-Mehr et al. 2006, Ordway et al.
2007, Yan et al. 2010, Yoon et al. 2010). GATA3 is essential in breast glandular cell
development. In particular, GATA3 is necessary for embryonic mammary development
and is actively involved in maintaining the differentiated state of luminal epithelial cells
of the mammary gland in adults (Kouros-Mehr et al. 2008, Kouros-Mehr et al. 2006, Yan
et al. 2010). In breast cancer, GATA3 has emerged as a strong and independent
predictor of tumor differentiation and clinical outcome (Amatori et al. 2010, Kouros-Mehr
et al. 2008, Kouros-Mehr et al. 2006, Ordway et al. 2007, Yan et al. 2010, Yoon et al.
2010). The low expression of GATA3 in breast cancer correlated with a poorer outcome
related to high tumor grade (poorly differentiated or undifferentiated), larger tumor size,
and short disease- free survival (Amatori et al. 2010, Kouros-Mehr et al. 2008, KourosMehr et al. 2006, Ordway et al. 2007, Yan et al. 2010, Yoon et al. 2010). The expression
of GATA3 also positively related to elevated E-cadherin, but decreased vimentin, Ncadherin and MMP-9, which suggests that GATA3 may drive the invasive breast cancer
cells to undergo the reversal of epithelial-mesenchymal transition, which can lead to the
inhibition of metastasis. Importantly, increasing GATA3 expression in the low expressing
MDA-MB-231 breast cancer cells led to cancer cells differentiating and decreased their
invasive potential in vitro (Chou et al. 2013, Chu et al. 2012, Yan et al. 2010), and
decreased tumor formation in vivo (Yan et al. 2010). Therefore, GATA3 is an important
prognostic marker and therapeutic target in breast cancer.
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Figure 4: Proportion of breast cancers defined by expression of the estrogen receptor
(ER), human epidermal growth factor 2 (Her2) and GATA3, together with prognosis
(Gaynor et al. 2013).

Efforts to develop drugs for breast cancer treatment have yielded many
successes. However, breast cancer remains the second leading cause of cancer death
in American women (Amatori et al. 2010). This high incidence of mortality highlights the
need for new therapeutics. One new potential source for therapeutics is plants used in
traditional Chinese medicine (TCM) which have been successfully used for treatment of
many diseases, including cancer (Medina-Franco et al. 2011, Newman 2008). Studies
of natural products, such as tea polyphenols, genistein, diadzein, equol, and grape seed
extracts, indicate that these agents either alone or in combination have the potential to
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be used as therapeutic agents in breast cancer (Fang et al. 2003, Newman 2008).

Dioscorea villosa (wild yam)

Plants belong to the genus Dioscorea is found in the tropical and temperate regions of
the world comprising more than 600 species. Dioscorea villosa is the North American
native of this genus and the roots and rhizomes of this species (Dioscorea villosa) are
known as wild yam. These plants contain steroidal saponins and are widely used as
botanical dietary supplements. Herbalists have been using wild yam to treat menstrual
cramps and other problems related to child birth, stomach upset and coughs (Carroll
2006). Dietary supplements containing wild yam extracts are used by women for
alleviation of menopausal symptoms and also served as an alternative to hormone
replacement therapy. The components of wild yam root extract (WYRE) belonging to
steroidal saponins and sapogenins are found to be noncarcinogenic (2004). To our
knowledge, fourteen steroidal saponins, two flavan-3-ol glycosides and fourteen
diarylheptanoids have been reported from wild yam (Ali, Smillie, and Khan 2013, Dong
et al. 2007, Hayes et al. 2007, Sautour, Miyamoto, and Lacaille-Dubois 2006, Yoon et al.
2010); among them diosgenin and dioscin exhibit anticancer activity (Jagadeesan et al.
2012). WYRE was able to reduce cell proliferation, increase the expression of
progesterone receptor and pS2 mRNA and down regulate ERα protein (Park et al.
2009). Moreover, diosgenein, (a steroidal saponin and aglycone of dioscin) isolated
from the rhizomes of wild yam, have the potential to stimulate the growth of mammary
epithelium of ovariectomized mice (Aradhana, Rao, and Kale 1992) and effectively
suppress fatty acid synthase expression in HER2-overexpressing breast cancer cells
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(Chiang et al. 2007). Dioscin, a plant glucoside saponin, was shown to inhibit autophagy
and enhance apoptosis in a number of human carcinoma cell lines with an IC 50 value
typically in uM concentrations (Hsieh et al. 2012, Liu et al. 2004, Mi et al. 2002, Cai et al.
2002, Chen et al. 2014, Gao et al. 2011, Wang et al. 2012). For instance, Liu et al, 2004
showed that dioscin was able to induce cytotoxicity and apoptosis in human myeloblast
leukemia HL-60 cells (Liu et al. 2004). Sun et al, 2011 demonstrated that dioscin
reversed effect on multi drug resistants in human hepatoma (HepG2/adriamycin cells)
(Sun, Zheng, et al. 2011). Gao et al, 2011 showed the G2/M phase arrest and apoptosis
effect in SGC-7901 (human gastric cancer cells) by dioscin (Gao et al. 2011). Also,
recently study by Chen et al 2014 showed that dioscin (1, 2 and 4 μM) could
significantly inhibit the viability of LNCaP cells in a time- and concentration-dependent
manner and apoptosis was an important mechanism by which dioscin inhibited prostate
cancer cells (Chen et al. 2014). However, there have been no studies reported
concerning the molecular mechanism of tumor invasion/migration reversion ability of
dioscin.
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Figure 5: A representative photograph of Wild Yam (Dioscorea villosa) A= Plant ; B=
Root

B

A

Figure 6: Structure of Dioscin (A) and Diosgenin (B) isolated from wild yam (Dioscorea
villosa) (Ali, Smillie, and Khan 2013).
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CHAPTER 2

CENTRAL HYPOTHESIS AND SPECIFIC AIMS

We hypothesized that wild yam has the potential to be used in breast cancer
therapy and their efficacy in epigenetic regulation need evaluation. Moreover, to our
knowledge, there have been no studies reported concerning the molecular mechanism
of tumor invasion/migration reversion by dioscin. Accordingly, we further investigate the
anti-tumor invasion/migration activity of dioscin.

Specific aim 1
Evaluate the efficacy of wild yam (Dioscorea villosa) as a potential GATA3
upregulators in human breast cancer cells.

Specific aim 2
Establish mechanism(s) of anti cancer activity of wild yam root extract (WYRE)
and its potential bioactive compounds.
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CHAPTER 3

MATERIALS AND METHODS

3.1 Cell culture
Human breast adenocarcinoma, MCF-7 (ER+) and MDA-MB-231 (ER) cells were
maintained in phenol red free DMEM-F12 (1:1) medium supplemented with 10%
dextran charcoal treated fetal bovine serum (Atlanta Biologicals, Atlanta, GA), 50 U/mL
penicillin and 50 µg/mL streptomycin as Pen-Strep (Life Technology, Grand Island, NY)
and 2 mM of L-glutamine (Life Technolgy, Grand Island, NY) at 37 0C in a humidified
atmosphere of 95% air and 5% CO2.

3.2 Cell viability assay and IC50 determination
MCF-7 and MDA-MB-231 cells in logarithmic growth were seeded at a density of 2x 104
cells/ well (for 24 h of incubation after adding treatments)

and 7.5x103 cells/ well (for

72 h of incubation after adding treatments) in 96 well plates and grown at 37 oC in a
humidified atmosphere of 95% air and 5% CO2 for 24 h. Stock of WYRE, dioscin and
diosgenin dissolved in DMSO at concentration of 2 mg/mL and 5-AZA at concentration
of 1 mM were diluted in serum-free medium supplemented with antibiotics and added to
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the wells to achieve the desired concentrations in a 250 µl final volume and incubated
for 72 h. Only dioscin was incubated for 24 h and 72 h. DMSO (0.01%) was used as
vehicle control. Cell viability was determined by XTT method(Scudiero et al. 1988). In
brief, 25 µl of 25 μM N-methyl dibenzopyrazine methyl sulfate-XTT (PMS-XTT) (SigmaAldrich, St. Louis, MO) solution was added to each well and incubated for 4 h at 37 0C.
The absorbance was measured by a spectrophotometer at 450 nm. Percent cell viability
was calculated compared to vehicle control.

3.3 RNA extraction

The MCF-7 and MDA-MB-231 cells (500 x 103 cells/ mL) were allowed to attach in the
25 cm3 culture flasks and cells were treated with various concentrations of WYRE (1050 μg/mL), 5-AZA (250-1000 nM), Dioscin (1.15-5.76 μM) and Diosgenin (2.41-24.14
μM)

for three days. After removing the medium completely, cells were trypsinized,

resuspended in the medium and counted. After washing twice with PBS, the cells were
used for RNA and DNA extraction by Trizol reagent following manufacturer’s instructions
(Invitrogen, Carlsberg, CA). Briefly, cells were lysed in Trizol reagent by repetitive
pipetting and incubated for 5 minutes at 15-30 0C then added 200 µL of chloroform per
1mL of Trizol reagent and caped sample tubes securely and shaked tubes vigorously by
hand for 15 seconds and incubated them at 15-30 0C for 2-3 minutes. Samples were
centrifuged at 12,000xg for 20 minutes at 4 0C. Following centrifugation, the mixture
separated into a lower red, phenol-chloroform phase, and a colorless upper aqueous
phase. The aqueous phase was transferred to fresh tube and precipitated the RNA by
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mixing with isopropyl alcohol. Then, samples were incubated at 15-30 0C for 10 minutes
and centrifuged at 12,000xg for 20 minutes at 4 0C. The supernatant was removed and
washed RNA pellet twice with 75% alcohol. At the end of the procedure, dry the RNA
pellet (air- dry) for 10 minutes. The extracted RNA samples were dissolved in nucleasefree water. Before cDNA synthesis, RNA samples were treated with RQ1 DNase
(Promega, Madison, WI) to ensure removal of contaminating genomic DNA. The
concentration of the RNA was determined by NanoDrop 2000c (Thermo Fisher
Scientific, Waltham, MA) and stored at -80 0C until analysis.

3.4 DNA extraction
The samples fractions remained after RNA fractions separations were utilized for DNA
extraction. DNA from the interphase and organic phase was precipitated with ethanol
and mixed samples by inversion. The samples were stored at room temperature for 2-3
minutes and sedimented by centrifugation at 2,000xg for 5 minutes at 4 0C. Then, the
samples were removed the phenol ethanol supernatant fraction, and washed the DNA
pellet twice in a solution containing 0.1M sodium citrate in 10% ethanol. At each wash,
DNA pellets were stored in the washing solution for 30 minutes at room temperature
with intermittent shaking and centrifuged at 2,000xg for 5 minutes at 4 0C. Following two
washes, the DNA pellets were suspended in 75% ethanol for 10- 20 minutes at room
temperature with periodic mixing and centrifuge at 2,000xg for 5 minutes at 4 0C. Finally,
air dried the DNA for 5-15 minutes in the open tube and dissolved DNA pellets in 8mM
NaOH. The concentration of the DNA was determined by NanoDrop 2000c (Thermo
Fisher Scientific, Waltham, MA) and stored at -20 0C until analysis.
32

3. 5 Quantitative real-time PCR (qPCR)
Gene-specific mRNA analysis was done by qPCR methods based either on PCR array
(SA BioScience, Valencia, CA) or by previously standardized methods (Hu, Khan, and
Dasmahapatra 2008, Livak and Schmittgen 2001, Wu et al. 2010). In brief, extracted
RNA was reverse transcribed to cDNA by iScript reverse transcriptase following the
manufacturer’s instructions (Bio-Rad, Hercules, CA). Two μL of cDNA in a final reaction
volume of 20 μL was amplified with gene-specific or internal controls (RPL-19) primers
either in PCR array plates (DNMT1, DNMT3A, DNMT3B, GATA3, ZFPM2, CDH1,
MMP9, and VIM) or in PCR tubes (TET1, TET2 and TET3). The primers (DNMT1,
DNMT3A, DNMT3B, GATA3, ZFPM2, CDH1, MMP9, VIM and RPL-19) used in the PCR
array were designed and added to the plates by the manufacturer (SA BioScience,
Valencia, CA), however, the primers used for TET enzyme mRNAs (TET1: GenBank
accession: NM_030625, sense: 5’-CCATATTATACACACCTTGGG-3’, anti-sense: 5’-CT
CCATGAACAGCCAAAAGAG-3’; TET2: GenBank accession: NM_017628, Sense:5’GGGCAGCCTTGTGGATGGCCC-3', Antisense:5'-GG AGCCCAGAGAGAGAAGGTT-3’;
TET3: GenBank accession: NM_144993, sense 5’-ATGGACTCAGGGCCAGTGTAC-3’,
antisense: 5’-GTTCCCAGCCTCACGACTCA TC-3’) and ACTB (GenBank accession:
BC002409,

sense:5’-AGCGAGCATCCCCCAAAGTT-3’,

antisense:

5’-

GGGCACGAAGGCTCATCATT-3’) were purchased from Integrated DNA Technologies
(IDT, Coralville, IA) and the nucleotide sequences of the amplified PCR products were
analyzed by a commercial source (Retrogen, San Diego, CA) and verified with
GenBank data base. The reaction conditions included an initial denaturation at 95 0C for
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3 min, one cycle, followed by 40 cycles of denaturation at 94 0C for 30 sec, annealing
60 sec at 60 0C, and extension 120 sec at 72 0C, fluorescence data collection for 1 sec.
After the end of each cycle the samples were incubated again for 1 sec at 78 0C and a
second set of fluorescence data collection was made to prevent error due to formation
of primer dimmers, if any. A final extension of one cycle at 72 0C for 10 min was made.
The melting curve was constructed by plotting fluorescence data (1 sec) against
temperature (65 0C to 95 0C with an interval of 0.2 0C and a holding time of 0.5 sec).
Each reaction was performed in duplicate. The cycle threshold or C (t) line was set at the
point where the signals surpass background noise and began to increase. This
threshold was applied to all wells for consistent analysis. For each sample, the
threshold cycle for internal standard (RPL19 or ACTB) amplification (Ct, RPL 19; Ct,
ACTB) was subtracted from the threshold cycle of the corresponding genes mRNA
amplification such as GATA3 was Ct, GATA3 to yield ΔCt. For each treatment group, the
mean ΔCt of control samples was subtracted from individual samples to yield individual
ΔΔCt. Fold induction relative to control samples was calculated by 2 -ΔΔCt.
To determine GATA3 mRNA copy, the internal standards were prepared in the
laboratory by amplifying cDNA with GATA3 gene-specific (GenBank Accession
NM_002051)

sense

(5'-CTCATTAAGCCCAAGCGAAGG-3')

and

antisense

(5'-

TTTTTCGGTTTCTGGTCTGG-3') primers (IDT, Coralvolle, IA) in a 20 μL final volume
containing buffer and other necessary ingredients including Taq DNA polymerase and
Mg2+ (Qiagen, Valencia, CA). The reaction conditions were: 94 0C 2 min 1 cycle,
followed by 40 cycles of denaturation 94 0C, 0.5 min, annealing 60 0 C, 1 min, extension
72 0 C, 2 min, and final extension 72 0C for 7 min, one cycle. The amplified PCR product
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was separated electrophoretically in 1% agarose gel containing 0.01% ethidium
bromide, eluted, and quantified in NanoDrop 2000c (Thermo Fisher Scientific, Waltham,
MA). The standards were (206 bp) aliquoted into separate tubes and stored at -80 0C
until use. During qPCR (DNA Engine Opticon 2, Bio-Rad), the standards were diluted to
require concentration (copy numbers) with nuclease free water and run in parallel with
the samples for amplification. The quantification cycle or Cq was set at the point
manually with the best R2 value ranged from 0.80-0.99 for standard curves. The copy
number of GATA3 mRNA in each sample tube was determined by using MJ Opticon
Monitor Analysis software, version 3.1 (Bio-Rad, Hercules, CA). The GATA3 mRNA
copy was expressed as mRNA copy /ng of total RNA.

3.6 Global DNA methylation and global DNA hydroxymethylation analysis
Global DNA methylation as 5-methylcytosine (5-mC) was determined by competitive
ELISA (Cell Biolabs, San Diego, CA) using anti-5'-methyl-2'-deoxycytidine (anti5MedCyd) monoclonal antibody by following the instructions provided by the
manufacturer. In brief, isolated genomic DNA was denatured at 95 0C for 5 min and then
rapidly chilled on ice. The samples (denatured DNA) were incubated at 37 0C for 2h with
P1 nuclease (Sigma-Aldrich, St. Louis, MO) in 20 mM sodium acetate buffer, pH 5.2.
Samples were further treated with alkaline phosphatase (NEB, Ipswich, MA) for 1 h at
37 0C in 100 mM Tris (pH 7.5). After centrifugation at 6000*g for 5 min the supernatant
was used for 5MedCyd ELISA assay. The color was developed by a secondary antibody
conjugated with HRP. The reaction was stopped after 1h by adding stop solution and the
plate was read at Spectra Max M5 (Molecular Devices, Sunnyvale, CA) at 450 nm. The
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data were calculated against a standard curve made from 5MedCyd run in parallel with
genomic DNA.
Hydroxymethylated DNA (5-hmC) was also determined by an ELISA-based protocol
(Cell Biolabs) with anti-5hmC antibody. In brief, the isolated DNA was diluted in PBS (2
μg/mL) and added to the wells of the DNA-High-Binding plate provided by the
manufacturer for adsorption. The DNA was adsorbed in wells overnight at 4 0C followed
by washing twice with PBS. After removal of excess PBS, 150 μL of assay diluents was
added to each well and incubated at room temperature for 1h with orbital shaking. The
wells were washed three times with 250 μL of wash buffer (1X) followed by addition of
150 μL of blocking reagent to each well. The plate was left at room temperature for 60
min, washed 3 times with wash buffer and 150 μL of HRP-conjugated secondary
antibody was added to each well. The wells were washed three times with wash buffer
followed by the addition of 100 μL of substrate to each well. After 30 min incubation at
room temperature 100 μL of stop solution were added to each well and read
immediately at 450 nm in a Spectra Max (M5).

3.7 Gene-specific methylation analysis of specific locations of GATA3 promoter
We have used genomic DNA for methylation analysis of a specific locus of GATA3
promoter using restriction endonuclease-sensitive analysis technique (Iida et al. 2006,
Oakeley 1999). The nucleotide information of GATA3 gene promoter were obtained from
Ensembl (www.ensembl.org) (GATA binding protein 3: Gene ID ENSG 00000107485)
considering 5000 bp upstream of ATG and the first exon which gave a total 5175
nucleotides for GATA3 promoter sequence. By using methyl primer express version 1.0
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software (Life Technology) we have detected three CpG islands in the promoter region
of GATA3 gene (defined as greater than 100 bp, greater than 50% GC, and greater than
60% observed/expected ratio). By designing gene-specific primers for GATA3 (sense:
5'-CTACCGGCTGGCTCCATTACC-3'

and

antisense:

5'-GTTGCTGTCTAACATTCA

CCG-3',) and using genomic DNA as a template, we were able to amplify a 580 bp
fragment for GATA3 (spanned from -1994 to -2573 nucleotide, ATG =+1) in PCR
conditions, 94 0C for 2 min, one cycle followed by denaturation at 94 0C, 30 sec,
annealing 62 0C, 1 min and extension 72 0C, 2 min, 40 cycle, final extension 7 min at 72
0

C. The nucleotide sequences were verified with the sequences reported in the data

base which showed 100% identity. Further analyses of the nucleotide sequences of the
amplified product of GATA3 (580 bp) consists thirty-two 5'-CG-3' sites and six 5'-CCGG3' sites. Once we confirmed about the amplified product, the extracted genomic DNA (1
μg) was digested separately with MspI, (40 units) and HpaII (20 units) restriction
endonuclease (RE) enzymes (NEB, Ipswich, MA) overnight at 37 0C in a 20 μL reaction
volume and inactivated for 20 min at 65 0C. Samples with equivalent amount of DNA in
identical conditions with no RE enzymes were used as uncut controls. Two μL of each of
RE digested DNA and parallel uncut controls were used for quantification by qPCR
using

GATA3

primers

as

target

and

ACTB

primers

(sense:

5'-

AGCGAGCATCCCCCAAAGTT-3' and antisense: 5'-GGGCACGAAGGCTCATCATT-3';
IDT, Coralville, IA) as internal controls. The genomic region annealed and amplified by
ACTB primers has no 5'-CCGG-3' sites, therefore, cannot be recognized by MspI or
HpaII RE and the amplified product should be intact (285 bp). The qPCR conditions
were identical as mentioned above. Each reaction was performed in duplicate. During
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analysis, the C(t) line was set at the point where the signals surpass background noise
and began to increase. This threshold was applied to all wells for consistent analysis of
target (GATA3) and ACTB amplification. For each sample, the threshold cycle for
internal standard (ACTB) amplification (Ct, ACTB) was subtracted from the threshold
cycle of the corresponding GATA3 amplification (Ct, GATA3)) to yield ΔCt. For each
treatment group, the ΔCt data of uncut control samples was subtracted from individual
samples including MspI and HpaII digested samples to yield individual ΔΔCt. Amplified
DNA products of GATA3 relative to uncut control samples was calculated by 2-ΔΔCt.

3.8 Protein extraction and Western Blot

MCF-7 or MDA-MB-231 cells were plated in 6-well plate in a concentration of 3x105
cells in 4 mL of growth medium. After 24 h dioscin at 1.15, 2.30, 5.76 μM and DMSO
(0.01%) was used as vehicle control were added and incubated at 37 0C in a humidified
atmosphere of 95% air and 5% CO2 for 72h. Cells were rinsed twice with ice-cold PBS
and collected by scraping and then extracted in a lysis buffer ( pH7.4) for 1 h at 4 0C
with occasional rocking. The lysates were passed through a 21- gauge needle (on ice)
to shear the DNA and centrifuged at 10,000xg for 20 mins at 4 0C. Supernatants were
collected for protein analysis. Supernatants were mixed with equal volume of 2X SDS
sample buffer, boiled for 5 mins and then separated through a 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (Biorad, Hercules, CA). After electrophoresis,
proteins were transferred to polyvinylidenefluoride membrane (Biorad, Hercules, CA)
and blocked with 5% nonfat dry milk (Santa Cruz Biotechnology, Dallas, TX) for 1h at
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room temperature. The membrane was immunoblotted with goat anti-GATA3 polyclonal
antibody (1:100) (Santa Cruz Biotechnology, Dallas, TX) at 4

0

C over night and

membrane was washed 3 times with washing buffer (Life Technology, Grand Island, NY)
and incubated in horseradish peroxidase-labeled donkey anti-goat antisera (1:2000)
(Santa Cruz Biotechnology, Dallas, TX) for 1 h at room temperature. Western blotting
luminol reagent (Santa Cruz Biotechnology, Dallas, TX) was used for detection of
GATA3 protein. Also, membrane was incubated with rabbit anti β-actin (1:2400) at 4 0C
over night, washed 3 times with washing buffer (Life Technology, Grand Island, NY) and
was incubated with biotin–conjugated goat anti-rabbit IgG for 1h at room temperature.
β-actin proteins were visualized with streptavidin-conjugated HRP.

3.9 Immunofluorescence and confocal microscopy

MDA-MB-231 and MCF-7 cells were plated in chamber slide (MERCK Millipore,
Billenrica, MA) at concentration 2.5x104 cells/well in 500 μL of growth medium. After 24
h dioscin at 5.76 μM and DMSO 0.01% (vehicle control) were added and incubated at
37 0C in a humidified atmosphere of 95% air and 5% CO 2 for 72h. Cells were fixed with
4% formaldehyde and blocked with PBS containing 5% BSA for 1h followed by
incubation with rabbit anti-GATA3 polyclonal antibody (1:50) (Santa Cruz Biotechnology,
Dallas, TX) overnight at 4 0C. Slides were washed 3 times with washing buffer (Life
Technology, Grand Island, NY). Then a goat anti-rabbit IgG fluorescein conjugated
secondary antibody (1:200) (Thermoscientific, Pittsburgh, PA) was added and incubated
for 1 h. Then slides were washed 3 times with washing buffer (Life Technology, Grand
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Island, NY) and counterstained with DAPI (Life Technology, Grand Island, NY).
Florescence was examined by confocal microscope LSM 510.

3.10 Wound healing assay
MDA-MB-231 cells were seeded into 24-well tissue culture plate at a density of 3x105
cells/well. After 24 hours of growth, cells reach ~70-80% confluence as a monolayer.
Then, the cell monolayers were gently and slowly scratched on with a micropipette tip
across the center of the well. After scratching, the wells were washed twice with medium
and replenished the wells with fresh medium that contained DMSO as control and
various concentrations of dioscin 1.15, 2.30, and 5.76 μM.

Each wells were

photographed under phase contrast microscope at 4X objectives at 0, 12, 18 and 24
hours. Pictures were analyzed by using Wimasis Image Analysis by IBIDI®, Verona, WI.

3.11 Cell migration assay
Cell migration was determined by using Boyden chambers with an 8 micron
polyethylene terephthalate (PET) membrane and detect the quantity of cell migration by
using fluorescein technique by following the instruction provided by manufacturer
(Trevigen, Gaithersburg, MD). Briefly, twenty-four hours prior to beginning assay,
starved cells in a serum- free medium to allow expression of free receptors. MDA-MB231 and MCF-7 cells preincubated with serum-free medium with DMSO as control and
various concentration of dioscin at 1.15, 2.30, and 5.76 μM were transferred onto top
invasion chamber with cell density of 50,000 cells/well. Using access port, added 150
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μL of medium per well to bottom chambers. The chambers were incubated at 37 0C in a
humidified atmosphere of 95% air and 5% CO2 for 24h. Then carefully aspirated top and
bottom chambers and washed with washing buffer. The top chamber was transfered to
assay chamber plate and added 100 μL of cell dissociation solution/Calcein–AM to
bottom chamber and incubated at 37 0C in a humidified atmosphere of 95% air and 5%
CO2 for 1h. Then, remove top chamber, the plates were read at 485nm excitation, 520
nm emission. Using standard curve converted Relative Fluorescence Units (RFU) to
cell numbers and determined cell migrations as percent of controls.

3.12 Cell invasion assay
Cell invasion was determined by employing Boyden chambers with an 8 micron
polyethylene terephthalate (PET) membrane that were coated with Basement
membrane Extract (BME) and detected the quantity of cell invasion by using fluorescein
technique by following the instruction provided by manufacturer. (Trevigen, Gaithersburg,
MD) Briefly, twenty-four hours prior to beginning assay, starved cells in a serum- free
medium to allow expression of free receptors. Coated membrane of top invasion
chamber with 0.5X BME solution and incubated for 4 h at room temperature. MDA-MB231 and MCF-7 cells preincubated with serum-free medium with DMSO as control and
various concentration of dioscin at 1.15, 2.30, and 5.76 μM were transferred onto top
invasion chamber with cells density of 50,000 cells/well. Using access port, added 150
μL of medium per well to bottom chambers. The chambers were incubated at 37 0C in a
humidified atmosphere of 95% air and 5% CO2 for 24h. Then carefully aspirated top and
bottom chambers and washed with washing buffer. The top chamber was transfered to
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assay chamber plate and added 100 μL of cell dissociation solution/Calcein-AM to
bottom chamber and incubated at 37 0C in a humidified atmosphere of 95% air and 5%
CO2 for 1h. Then, remove top chamber, the plates were read at 485nm excitation, 520
nm emission. Using standard curve converted Relative Fluorescence Units (RFU) to
cell numbers and determined cell invasion as percent of controls.

3.13 Statistics
Statistical significance was assessed using an unpaired t-test or one-way ANOVA
followed by Tukey’s post-hoc multiple comparison test to evaluate the

differences

between control and various treatment groups with the use of GraphPad Prism version
5.0 (GraphPad Software, San Diego, CA). The data were presented as mean  SEM
and p<0.05 was considered as significant.
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CHAPTER 4
RESULTS

1.1 Identification of CpG islands in GATA3 gene promoter.
Methyl Primer Express V1.0 software (Applied Bioscience) was used for searching CpG
islands on the nucleotides (5175 nucleotides located upstream of ATG in GATA3 gene)
using CpG island size 200-2000 bp. C+Gs/ total bases >50% and CpG observed/CpG
expected <0.6. There are three CpG rich sites in the promoter region of GATA3 and
CpG island were 2000, 2000, and 988 bp.

Table 1. Distribution of CpG islands of GATA3 gene by using Methyl Primer Express
V1.0 (Applied Bioscience). There are three CpG rich sites in the promoter region of
GATA3.
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1.2 Effects of WYRE on GATA3 mRNA expression as copy number
GATA3 mRNA analysis as copy number indicates that MCF-7 cells have comparatively
higher copy numbers of GATA3 mRNA than MDA-MB-231 cells. WYRE at the doses of
25-50 μg/mL was able to significantly increase GATA3 mRNA copy numbers in both cell
lines when compared with controls (Figure 8).
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Figure 7: Constant number of cells (500 x10 3) were cultured in 25 cm3 cell culture
flasks and cells were treated with WYRE (0-50 µg/mL) for 72 h. After removing the
medium completely, the cells were trypsinized, resuspended in the medium and counted.
Total RNA was extracted from cell pellets by Trizol reagent and used for mRNA analysis
by copy numbers against GATA mRNA standard curve. Each bar is the mean SEM of
eight observations. Bar head with asterisks (*) indicate that the data are significantly
different from controls. The GATA3 mRNA expression was found to be enhanced in a
concentration-dependent manner in both cell lines. GATA3 mRNA expression in MCF-7
cells was higher (approximately 10 fold) than in MDA-MB-231 cells.
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1.3 Effects of WYRE and 5-AZA on GATA3 mRNA expression.

GATA3 mRNA expression relative to RPL19 was increased significantly in both MCF-7
and MDA-MB-231 cells treated with 50 μg/mL WYRE. Lower concentrations of WYRE
(10-35 μg/mL) were unable to alter GATA3 mRNA content in both cell lines (Figure 8.1).
Moreover, GATA3 mRNA content relative to RPL19 was increased significantly only in
MDA-MB-231 cells at 1 μM of 5-AZA. Other 5-AZA concentrations in MDA-MB-231 cells
were unable to alter GATA3 mRNA expression. Also, MCF-7 cells were irresponsive to
5-AZA (250-1000 nM) (Figure 8.2).
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Figure 8: Constant number of cells (500 x10 3) were cultured in 25 cm3 cell culture
flasks and cells were treated with WYRE (0-50 µg/mL) and 5-AZA (0-1000 nM) for 72 h.
After removing the medium completely, the cells were trypsinized, resuspended in the
medium and counted. Total RNA was extracted from cell pellets by Trizol reagent and
used for mRNA analysis by PCR array using RPL19 as internal control. Each bar is the
mean  SEM of eight observations. Bar head with asterisks (*) indicate that the data are
significantly different from controls. The GATA3 mRNA expression was found to be
enhanced in a 50 µg/mL of WYRE in both cell lines (Figure 8.1). Moreover, GATA3
mRNA content relative to RPL19 was increased significantly only in MDA-MB-231 cells
at 1 μM of 5-AZA. Other 5-AZA concentrations in MDA-MB-231 cells were unable to
alter GATA3 mRNA content. Also, MCF-7 cells were irresponsive to any concentrations
of 5-AZA (250-1000 nM) (Figure 8.2).
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1.4 Expression of GATA3 protein in MCF-7 and MDA-MB-231 cells
Cell lysates from MCF-7 and MDA-MB-231 cells were used for immunoblotting using
polyclonal antibody specific for GATA3 and β- actin as loading control. Protein
expression of GATA3 in MCF-7 cells was found to be higher than MDA-MB-231cells
(Figure 9).
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Figure 9: Protein expression of GATA3 in MCF-7 cells was detected higher than MDAMB-231cells. P = positive control (GATA3 lysate from Santa Cruz Biotechnology, Dallas,
TX) MC=MCF-7 and MD=MDA-MB-231 cells.

1.5 Effects of WYRE on global DNA methylation pattern of MCF-7 and MDA-MB231 cells.
Global DNA methylation pattern as 5-mC was determined as 5’-methyl-2’-deoxycytidine
(5MedCyd) content in the genomic DNA following a commercial ELISA kit protocols
(Cell Biolabs). It was observed that 5-mC levels were identical in both cells (2232 72
nM / 10 μg DNA in MCF-7 and 2349 59 nM/10 μg DNA in MDA-MB-231 cells). WYRE
at 10μg/mL and 50μg/mL concentrations was able to increase the 5-mC content in
MCF-7 cells significantly (5.02% and 9.27% increase over control, respectively). Other
concentrations (25 and 35 μg/mL) did not reach statistical significance. In MDA-MB-231
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cells, WYRE did not show any significant increase in the 5-mC content compared to
controls (Figure 10.1). The genomic DNA was also used for 5-hydroxymethylcytosine (5hmC) analysis. It was observed that in MCF-7 cells 5-hmC content remained unaltered
while in MDA-MB-231 cells 5-hmC levels were significantly decreased by all
concentrations of WYRE used in this study (10-50 μg/mL) when compared with the
corresponding controls (Figure 10.2).
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Figure 10: Effect of WYRE on global DNA methylation of MCF-7 and MDA-MB-231 cells.
Global DNA methylation was determined as 5-mC and 5-hmC by following a method
developed by manufacturer (Cell Biolab). Cells were treated with WYRE (0-50 µg/mL)
for 72 h. DNA was extracted by Trizol reagents and used for analysis. Each bar is the
mean SEM of four observations. Bar head with asterisks (*) indicate that the data are
significantly different from controls. The 5-mC level was found to be significantly
different from controls only in MCF-7 cells (50 μg/mL), however, 5-hmC level was
significantly different in MDA-MB-231 cells (10-50 μg/mL). Figure 10.1= 5-mC and
Figure 10.2= 5-hmC

1.6 Effects of WYRE on DNMT1, DNMT3A, DNMT3B, TET1, TET2, and TET3 mRNA
contents of MCF-7 and MDA-MB-231 cells.
The quantitative mRNA analysis of three DNMT enzymes (DNMT1, 3A and 3B) and TET
family of enzymes (TET1, TET2, and TET3) was done in WYRE-treated MCF-7 and
MDA-MB-231 cells by PCR array based technology. It was observed that mRNA
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contents of DNMT1, 3A, and 3B were increased in both cell lines in a concentrationdependent manner. The increase was significant in MCF-7 cells treated with 50 µg/mL
of WYRE whereas, a significant increase was observed in MDA-MB-231 cells treated
with 25 and 50 μg/mL of WYRE as compared to controls (Figure 11). The TET1, TET2
and TET3 mRNA contents in MCF-7 cells were remained unalter; however, MDA-MB231 cells treated with 50 µg/mL of WYRE showed enhanced TET 3 mRNA expressions
(Figure 12).
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Figure 11: Effect of WYRE on DNMT1, DNMT3A, and DNMT3B mRNA content of MCF7 and MDA-MB-231 cells. Total RNA was extracted by Trizol reagent and used for
DNMT1, DNMT3A and DNMT3B mRNA analysis by PCR array. RPL19 was used as
internal control. Each bar is the mean  SEM of eight observations. Bar head with
asterisks (*) indicate that the data are significantly different from controls. The mRNA
expressions of these three genes were enhanced in a concentration-dependent manner
in both cell lines. Figure 11.1= DNMT1, Figure 11.2= DNMT3A, Figure 11.3=DNMT3B.
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Figure 12: Effect of wild yam root extract on TET1, TET2, and TET3 mRNA content of
MCF-7 and MDA-MB-231 cells. Total RNA was extracted by Trizol reagent reagent and
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used for TET1, TET2, and TET3 mRNA analysis by PCR array. ACTB was used as
internal control. Each bar is the mean  SEM of eight observations. Bar head with
asterisks (*) indicate that the data are significantly different from controls. Figure 12.1=
TET1; Figure 12.2= TET2; Figure 12.3= TET 3

1.7 Effects of WYRE on the locus-specific DNA methylation pattern of GATA3
promoters.
The amplified GATA3 promoter is spanned 580 bp (-1994 to -2573 bp considering ATG=
+1) and consists of thirty two 5’-CG-3’ and six 5’-CCGG-3’ sites which can be
recognized by HpaII, however, it cannot be cleaved if the internal C (cytosine) is
methylated. The HpaII isoschizomer MspI can also recognize 5’-CCGG-3’ and cleave
the site irrespective of the methylation status of the internal C. If the outer C is
methylated than neither of the enzymes (Msp1 or Hpa II) can recognize the 5’-CCGG-3’
site. Therefore, difference in the extent of fragmentation of genomic DNA between these
two endonucleases indicates variation of methylation in 5’-CG-3’ sites. Our data showed
that in both MCF-7 and MDA-MB-231 cells the amplified GATA3 DNA content in uncut
(no endonuclease treatment) and HpaII digested genomic DNA are identical in control
and WYRE-treated cells which indicate that the inner C in all six 5’-CCGG-3’ site of
GATA3 promoter are methylated at this locus. Treatment of WYRE (50 μg/mL) is unable
to alter methylation in these sites (inner Cs). However, we have observed significant
variation when we compared the amplified DNA of uncut control and HpaII digested
DNA with the DNA amplified from Msp1digested DNA. As Msp1 can recognize 5’CCGG-3’ sites irrespective of inner C methylation, we expect that the genomic DNA
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amplification will either be neglible or undetectable. In both control and WYRE-treated
MCF-7 cells, the amplified DNA of Msp1 digested genomic DNA was significantly lower
than the amplified DNA obtained either from uncut or HpaII digested genomic DNA
which also indicates that the outer C in all six 5’-CCGG-3’ site of GATA3 locus is not
methylated and remained unaltered by WYRE (50 μg/mL). However, in MDA-MB-231
cells, the amplified product of Msp1 digested genomic DNA in control cells was identical
with uncut control, but significantly different from the DNA amplified by Hpa II digested
genomic DNA. Therefore the methylation of outer C of 5’-CCGG-3’ sites of GATA3 in
this locus is likely to be different in MDA-MB-231 cells than MCF-7 cells. In contrast, in
WYRE treated cells the amplified DNA of Msp1 digested genomic DNA is significantly
different (lower) from the amplified DNA of both uncut and Hpa II digested genomic DNA
indicating demethylation in outer C of all the six 5’-CCGG-3’ sites of GATA3 locus exists
in MDA-MB-231 cells (Figure 14).
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Figure 14: Effect of WYRE on GATA3 promoter analysis of MCF-7 and MDA-MB-231
cells. Cells were treated with WYRE (0-50 µg/mL) for 72 h. DNA was extracted by Trizol
reagents and used for promoter analysis. Genomic DNA was digested with buffer
(uncut), HpaII, and Msp1 RE overnight and used for amplification with GATA3 gene57

specific primers. ACTB was used as internal control. The amplified PCR products were
separated on 2% agarose gel (upper panel). GATA3 band is at 580 bp and ACTB band
is at 283 bp region. U=amplified product of uncut (not digested with RE) genomic DNA,
H= amplified product of HpaII digested genomic DNA, M= amplified product of Msp1
digested genomic DNA. 500= 500 bp, 100= 100 bp. Distinct GATA3 and ACTB bands
are observed in U and H lanes whereas in M lanes the GATA3 bands are either faint or
absent in contrast to ACTB bands. The histogram (lower panel) is the GATA3 promoter
methylation analysis of amplified genomic DNA obtained after RE digestion. Each bar is
the mean SEM of four observations. Bar head with asterisks (*) indicate the data are
significantly different from controls. Bar head with pound symbol (#) indicates that the
data are significantly different from HpaII digested samples.

2.1 Effects of dioscin and diosgenin on cell viability at 72 h
We examined the effects of dioscin and diosgenin on the viability of MCF-7 and MDAMB-231 cells in vitro. The cells were treated with various concentrations of dioscin and
diosgenin for 72 h and cell viability was determined by XTT method. It was observed
that dioscin was able to decrease the cell viability at 72 h in a concentration-dependent
manner with calculated IC50 of 3.85 and 2.07 μM for MCF-7 and MDA-MB-231 cells,
respectively. Diosgenin was also able to decrease the cell viability at much higher
concentrations than dioscin. Calculated IC50 of diosgenin were greater than 24.13 and
20.10 μM for MCF-7 and MDA-MB-231 cells, respectively (Figure 14).
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Figure 14: Effect of dioscin and diosgenin on cell viabilities of MCF-7 and MDA-MB-231
cells. Cells were treated with various concentrations of dioscin and diosgenin for 72 h.
Cell viability is presented as mean ± SEM of eight independent experiments
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2.2 Effect of diosgenin and dioscin on GATA3 mRNA content
Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with either
diosgenin (0-24.14 µM) or dioscin (0-5.76 µM) and used for GATA3 mRNA analysis by
PCR array. RPL19 was used as internal control. The GATA3 mRNA content were
unaltered in MDA-MB-231 cells treated with diosgenin at all concentrations used in this
study (2.41-24.14 µM) (Figure 15). However, mRNA expressions of GATA3 were
enhanced at concentration of 5.76 µM of dioscin. Lower concentrations of dioscin (1.152.30 µM) were unable to alter GATA3 mRNA content (Figure 16).
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Figure 15: Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated
with diosgenin (0-24.14 µM) and used for GATA3 mRNA analysis by PCR array. RPL19
was used as internal control. The GATA3 mRNA content were remained unaltered in
MDA-MB-231 cells treated with diosgenin at all concentrations used in this study (2.4160

24.14 µM). Each bar is the mean  SEM of eight observations. Bar head with asterisks
(*) indicate that the data are significantly different from controls.
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Figure 16: Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated
with dioscin (0-5.76 µM) and used for GATA3 mRNA analysis by PCR array. RPL19 was
used as internal control. The mRNA expressions of GATA3 were enhanced at a
concentration of 5.76 µM of dioscin. Dioscin at 1.15-2.30 µM was unable to alter GATA3
mRNA expression when compared with controls. Each bar is the mean  SEM of eight
observations. Bar head with asterisks (*) indicate that the data are significantly different
from controls.
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2.3 Dioscin enhances the GATA3 protein expression in MDA-MB-231 cells

To validate the mRNA results, we did western blots using a polyclonal antibody specific
for GATA3 on MDA-MB-231 cells treated with dioscin (1.15-5.76 µM). We also used 5Aza which is a known demethylating agent and GATA3 lysate from Santa Cruz
Biotechnology, Dallas, TX as positive controls. Our results showed that GATA3 protein
expression was enhanced in a concentration- dependent manner in MDA-MB-231 cells
treated with dioscin (Figure 17).
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Figure 17:

Representative figure showing the effect of dioscin on GATA3 protein

expression in MDA-MB-231 cells by using a polyclonal antibody specific for GATA3 on
MDA-MB-231 cells treated with dioscin (1.15-5.76 µM), 1 µM of 5-AZA and GATA3
lysate from Santa Cruz Biotechnology, Dallas, TX as positive controls.
used as loading control.

β- actin was

The data indicated that GATA3 protein expression was

enhanced in MDA-MB-231 cells treated with dioscin (1.15-5.76 µM) and 5-AZA (1µM)
compared with controls. DC=dioscin, 5-AZA= 5-Azacytidine, P= positive control (GATA3
lysate from Santa Cruz Biotechnology, Dallas, TX)

2.4 Dioscin enhances the GATA3 protein expression in both MCF-7 and MDAMB-231 cells
We next confirmed whether dioscin enhanced GATA3 protein expression in triple
negative breast cancer cell line by comparing expression in MDA-MB-231 cells with
MCF-7 cells which are known as ER+ and have higher GATA3 expression than MDAMB-231 cells. Immunocytochemical analysis of GATA3 protein expression was used in
MCF-7 cells (A-D) and MDA-MB-231 (E-H) cells. The cells were fixed in 4% PFA and
stained with rabbit anti-GATA3 polyclonal antibody and counterstained by DAPI and
examined by a confocal microscope LSM 510. A,E =control. B,F= cells treated with 5.76
μM of dioscin. C,G = magnified to 40X of cells treated with 5.76 μM of dioscin. D,H=
representative MCF-7 and MDA-MB-231 cell morphology. Both MCF-7 and MDA-MB231 cells after treating with dioscin showed increased the GATA3 protein expression
compared with controls (Figure 18).
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Figure 18:

Immunocytochemical analysis of GATA3 protein expressed in

MCF-7 cells (A-D) and MDA-MB-231 (E-H) cells. The cells were fixed in 4%
PFA and

stained with

rabbit anti-GATA3

polyclonal antibody

and

counterstained by DAPI. Cells were examined by a confocal microscope
LSM510. A,E =control. B,F= cells treated with 5.76 μM of dioscin. C,G =
magnified to 40X of cells treated with 5.76 μM of dioscin. D,H=
representative MCF-7 and MDA-MB-231 cell morphology. Both MCF-7 and
MDA-MB-231 cells after treatment with dioscin increased the GATA3 protein
expression when compared with controls.

64

2.5 Effect of dioscin on ZFPM2 mRNA expression in MCF-7 and MDA-MB-231
cells
Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells treated
with dioscin (0-5.76 µM) and used for ZFPM2 mRNA analysis by PCR array. RPL19 was
used as internal control. The mRNA expression of ZFPM2 was enhanced significantly at
a concentration of 5.76 µM of dioscin in both cell lines when compared with
corresponding controls. Other concentrations of dioscin (1.15-2.30 µM) remained
ineffective in altering ZFPM2 mRNA expression in both cell lines (Figure 19).
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Figure 19: Effect of dioscin on ZFPM2 mRNA expression in MCF-7 and MDA-MB-231
cells. Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells
treated with dioscin (0-5.76 µM) and used for ZFPM2 mRNA analysis by PCR array.
RPL19 was used as internal control. The mRNA expression of ZFPM2 was enhanced at
a concentration of 5.76 µM of dioscin in both cell lines. Lower concentrations of dioscin
(1.15-2.30 µM) were unable to alter ZFPM2 mRNA content in both cell lines. Each bar is
the mean  SEM of eight observations. Bar head with asterisks (*) indicate that the data
are significantly different from controls.

2.6 Effect of dioscin on CDH1 (E-Cadherin) mRNA expression in MCF-7 and MDAMB-231 cells

Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells treated
with dioscin (0-5.76 µM) and used for CDH1 mRNA analysis by PCR array. RPL19 was
used as internal control. The mRNA expressions of CDH1 were enhanced at a
concentration of 5.76 µM of dioscin in both cell lines. Lower concentrations of dioscin
(1.15-2.30 µM) were unable to alter CDH1 mRNA content in both cell lines (Figure 20).
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Figure 20: Effect of dioscin on CDH1 mRNA expression in MCF-7 and MDA-MB-231
cells. Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells
treated with dioscin (0-5.76 µM) and used for CDH1 mRNA analysis by PCR array.
RPL19 was used as internal control. The mRNA expression of CDH1 was enhanced at
a concentration of 5.76 µM of dioscin in both cell lines. Lower concentrations of dioscin
(1.15-2.30 µM) were unable to alter CDH1 mRNA content in both cell lines. Each bar is
the mean  SEM of eight observations. Bar head with asterisks (*) indicate that the data
are significantly different from controls.

2.7 Effect of dioscin on MMP9 mRNA content in MDA-MB-231 cells

Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin
(0-5.76 µM) and used for MMP9 mRNA analysis by PCR array. RPL19 was used as
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internal control. The mRNA expression of MMP9 was suppressed at a concentration of
2.30 µM of dioscin. Lower concentration of dioscin at 1.15 µM and higher concentration
of dioscin (at 5.76 µM) were unable to alter MMP9 mRNA content when compared with
corresponding controls (Figure 21).
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Figure 21: Effect of dioscin on MMP9 mRNA expression in MDA-MB-231 cells. Total
RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin (05.76 µM) and used for MMP9 mRNA analysis by PCR array. RPL19 was used as
internal control. The mRNA expression of MMP9 was decreased in only concentration of
dioscin 2.30 µM. Each bar is the mean  SEM of eight observations. Bar head with
asterisks (*) indicate that the data are significantly different from controls.
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2.8 Effect of dioscin on Vimentin mRNA expression in MDA-MB-231 cells
Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin
(0-5.76 µM) and used for VIM mRNA analysis by PCR array. RPL19 was used as
internal control. The mRNA expressions of VIM were reduced at a concentration of 2.30
and 5.76 µM of dioscin. Lower concentration of dioscin at 1.15 µM was unable to alter
VIM mRNA content. (Figure 22)
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Figure 22: Effect of dioscin on Vimentin mRNA expression in MDA-MB-231 cells Total
RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin (05.76 µM) and used for VIM mRNA analysis by PCR array. RPL19 was used as internal
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control. The mRNA expressions of VIM were reduced at a concentration of 2.30 and
5.76 µM of dioscin. Lower concentration of dioscin at 1.15 µM was unable to alter VIM
mRNA content. Each bar is the mean  SEM of eight observations. Bar head with
asterisks (*) indicate that the data are significantly different from controls.

2.9 Effects of dioscin on MCF-7 and MDA-MB-231 cell viability after 24 h of
treatment

We examined the effects of dioscin on viability of MCF-7 and MDA-MB-231 cells in vitro
after 24h of treatment. The cells were treated with various concentrations of dioscin (023.03 μM) for 24 h and cell viability was determined by XTT method. It was observed
that dioscin was able to decrease the cell viability at 24 h in a concentration-dependent
manner with calculated IC50 of 13.70 and 6.77 μM for MCF-7 and MDA-MB-231 cells,
respectively (Figure 23).
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Figure 23: Effect of dioscin on viabilities of MCF-7 and MDA-MB-231 cells after 24h of
treatment. Cells were treated with various concentrations of dioscin (0-23.03 μM) for 24
h. Cell viability is presented as mean ± SEM of eight independent experiments. Bar
head with asterisks (*) indicate that the data are significantly different from controls.

2.10 Dioscin inhibit migration in MDA-MB-231 cells
After MDA-MB-231 cells incubated with different concentrations of dioscin (0.58, 1.15,
2.30 and 5.76 µM) for 12h, 18h and 24h, dioscin could suppress migration of MDA-MB231 cells in both concentration- and time- dependent manner. These results revealed
that dioscin inhibited the motility of MDA-MB-231 cells significantly when compared with
corresponding controls (Figure 24-29).
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Figure 24: Effect of dioscin on migration of MDA-MB-231 cells. Cell monolayers were
scraped by sterile micropipette tip and the cells were treated with various concentrations
of dioscin for 24 h. Cells migrated to wounded region over time and were photographed
(4X magnification). Photographs were taken at 0, 12, 18 and 24h and analyzed by
WIMasis image analysis program by IBIDI®.
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Figure 25: Effect of dioscin on migration of MDA-MB-231 cells. Cell monolayers were
scraped by sterile micropipette tip and the cells were treated with various concentrations
of dioscin (1.15, 2.30 and 5.76 µM). Cells migrated to wounded region were
photographed (4X magnification) at 0h and analyzed by WIMasis image analysis
program by IBIDI®.
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Figure 26: Effect of dioscin on migration of MDA-MB-231 cells. Cell monolayers were
scraped by sterile micropipette tip and the cells were treated with various concentrations
of dioscin (1.15, 2.30 and 5.76 µM) for 12 h (A) cells migrated to wounded region were
photographed (4X magnification) at 12h and analyzed by WIMasis image analysis
program by IBIDI® (B) The scratch area of cell cultures were quantified from three
independent experiments. Data are presented as mean ± SEM of three independent
experiments. Bar head with asterisks (*) indicate that the data are significantly different
from controls.
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Figure 27: Effect of dioscin on migration of MDA-MB-231 cells. Cells monolayers were
scraped by sterile micropipette tip and the cells were treated with various concentrations
of dioscin (1.15, 2.30 and 5.76 µM) for 18 h (A) cells migrated to wounded region were
photographed (4X magnification) at 18h and analyzed by WIMasis image analysis
program by IBIDI® (B) The scratch area of cell cultures were quantified from three
independent experiments. Data are presented as mean ± SEM of three independent
experiments. Bar head with asterisks (*) indicate that the data are significantly different
from controls.
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Figure 28: Effect of dioscin on migration of MDA-MB-231 cells. Cells monolayers were
scraped by sterile micropipette tip and the cells were treated with various concentrations
of dioscin (1.15, 2.30 and 5.76 µM) for 24 h (A) cells migrated to wounded region were
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photographed (4X magnification) at 24h and analyzed by WIMasis image analysis
program by IBIDI® (B) The scratch area of cell cultures were quantified from three
independent experiments. Data are presented as mean ± SEM of three independent
experiments. Bar head with asterisks (*) indicate that the data are significantly different
from controls.
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Figure 29: Effect of dioscin on migration of MDA-MB-231 cells. Cells monolayers were
scraped by sterile micropipette tip and the cells were treated with various concentrations
of dioscin (1.15, 2.30 and 5.76 µM) for 24 h (A) cells migrated to wounded region were
photographed (4X magnification) and analyzed by using WIMasis image analysis by
IBIDI® (B) The scratch area of cell cultures were quantified from three independent
experiments. Data are presented as mean ± SEM of three independent experiments.
Bar head with asterisks (*) indicate that the data are significantly different from controls
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2.11 Effect of cellular migration in MCF-7 and MDA-MB-231 cells
Cell migration was determined by using Boyden chambers with an 8 micron
polyethylene terephthalate (PET) membrane and detected the quantity of cell migration
by using fluorescein technique. MDA-MB-231 cells which are triple negative breast
cancer cells had higher migration activity when compared with MCF-7 cells which are
ER+ and have higher expression of GATA3 statistic significantly (Figure 30).
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Figure 30: Comparison of cell migration between MCF-7 and MDA-MB-231 cells. It was
observed that the migration of MDA-MB-231 cells was significantly higher when
compared with MCF-7 cells. Data are presented as mean ± SEM of twelve independent
experiments. Bar head with asterisks (*) indicate that the data are significantly different
from controls
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2.12 Effect of dioscin on cellular migration in MCF-7 and MDA-MB-231 cells
To validate the anti migration effect of dioscin in MDA-MB-231cells and analyzed the
cellular migration of MCF-7 cells, we employed Boyden chambers with an 8 micron
polyethylene terephthalate (PET) membrane and detect the quantity of cell invasion by
using fluorescein technique (Trevigen, Gaithersburg, MD) in both cell lines. The results
showed that dioscin could inhibit the cell migration at 5.76 µM in both MCF-7 and MDAMB-231 cells when compared with corresponding controls (Figure 31).
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Figure 31:

Effect of dioscin on cellular migration in MCF-7 and MDA-MB-231cells.

Dioscin 5.76 µM could suppress migration of MDA-MB-231 and MCF-7 cells when
compared with corresponding controls. Data are presented as mean ± SEM of six
independent experiments. Bar head with asterisks (*) indicate that the data are
significantly different from controls.
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2.13 Effect of dioscin on cellular invasion in MCF-7 and MDA-MB-231 cells
To analyzed the effect of dioscin on cellular invasion of MCF-7 and MDA-MB-231 cells,
we employed Boyden chambers with an 8 micron polyethylene terephthalate (PET)
membrane that coated with Basement membrane Extract (BME) and detected the
quantity of cell invasion by using fluorescein technique (Trevigen, Gaithersburg, MD) in
both cell lines. The results showed that dioscin could suppress invasion of MDA-MB231 and MCF-7 cells across basement membrane coated filter. Treatment with dioscin
of 5.76 µM inhibited 65% and 60% of cell invasion in MDA-MB-231 and MCF-7 cells,
respectively. The results indicated that dioscin markedly inhibited invasion of both cell
lines (Figure 32).
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Figure 32:

Effect of dioscin on cellular invasion in MCF-7 and MDA-MB-231cells.

Dioscin suppressed invasion of MDA-MB-231 and MCF-7 cells across basement
membrane coated filter. Treatment with dioscin of 5.76 µM inhibited 65% and 60% of
cell invasion in MDA-MB-231 and MCF-7 cells, respectively. Data are presented as
mean ± SEM of six independent experiments. Bar head with asterisks (*) indicate that
the data are significantly different from controls
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CHAPTER 4.

DISCUSSION

Although efforts to develop drugs for breast cancer treatment have yielded many
successes, breast cancer remains the second leading cause of cancer death in
American women (Amatori et al. 2010). This high incidence of mortality highlights the
need for new therapeutics. The mechanisms associated with breast cancer are genetic
alterations

including

specific

gene

amplifications,

deletions,

point

mutations,

chromosome rearrangementd and aneuploidy; however, breast cancer is also driven by
epigenetic mechanism (Dworkin, Huang, and Toland 2009a, Jovanovic et al. 2010,
Kress et al. 2010). These epigenetic alterations do not affect the primary DNA sequence
and occur through three mutually interacting events, namely DNA methylation, histone
modifications and nucleosomal remodeling. These events modulate chromatin structure,
and in turn activate or silence gene expression (Lo and Sukumar 2008). Epigenetic
therapy is potentially useful because epigenetic defects are thought to be more easily
reversible when compared with genetic defects (Kristensen, Nielsen, and Hansen 2009).
Moreover, in breast cancer cells, a variety of genes participating in different cellular
processes such as cell cycle inhibition (p16RASSF1A), DNA repair (BRCA1),
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proapoptotic processes (HOX5, TMS1), metabolic events (GSTP1), cell adhesion and
metastatic processes (CDH1, CDH13) are affected by epigenetic modifications
(Widschwendter and Jones 2002). Analysis of both primary invasive breast cancer and
normal breast samples by genome-wide methylation array technology identified higher
frequency of methylation in ER+ tumors (5264 loci) compared to ER- tumors (3112
loci)(Fackler et al. 2011, Connolly and Stearns 2012). Also several other studies in
breast cancer cells identified genes (APC, BINI, BMP6, BRACA1, CST6, ESRb, GSTP1,
PI6, P21, and TIMP3) which are functionally silent due to inappropriate promoter
hypermethylation (Radpour R et al. 2009). A recent study in ER+ and ER- breast cancer
cell lines identified genes including GATA3 which were hypermethylated and silent in
ER- cells but hypomethylated and active in ER+ cells (Sun, Asmann, et al. 2011). One
new potential source for therapeutics of breast cancer is plants used in traditional
Chinese medicine (TCM) which have been successfully used for treatment of many
diseases, including cancer (Medina-Franco et al. 2011, Newman 2008). Studies of
natural products such as tea polyphenols, genistein, diadzein, and equol indicate that
these compounds either alone or in combination have the potential to be used as
therapeutic agents in breast cancer (Fang et al. 2003, Newman 2008). Therefore, we
evaluated the efficacy of WYRE as a potential modulator of DNA methylation and
function by using both ER+ (MCF-7) and ER- (MDA-MB-231) cells and concentrated on
GATA3 gene which is considered as an important marker of breast cancer progression
(Tominaga et al. 2012, Chou et al. 2013).
Our data indicated that WYRE was able to increase the expression of GATA3 mRNA in
both ER+ (MCF-7) and ER- (MDA-MB-231) human breast cancer cells in a
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concentration-dependent manner (Figure 7). Also, WYRE was able to reduce in vitro
cell viability of both cell lines. Moreover, MCF-7 cells have approximately 10-fold higher
GATA3 mRNA copy number (Figure 7) and 4-fold higher GATA3 protein level than MDAMB-231 cells (Figure 9). As the response of both cell lines to WYRE enhanced in
GATA3 mRNA expression, we anticipate that WYRE might be able to alter the
methylation status in GATA3 gene in both cell lines. A recent study in ER+ and ERbreast cancer cell lines identified GATA3 gene, which were hypermethylated and silent
in ER- cells but hypomethylated and active in ER+ cells (Sun, Asmann, et al. 2011,
Chou et al. 2013, Hoch et al. 1999, Yan et al. 2010, Yoon et al. 2010). There are reports
that in breast cancer cells, GATA3 mRNA expression is ERα-dependent, the expression
of this gene was observed only in ER+ cells (MCF-7 and BT474) but not in ER (Licata
et al. 2010, Hoch et al. 1999, Yan et al. 2010). Therefore, we predict that, WYRE is able
to enhance GATA3 mRNA expression either by up-regulating ER as in ER+ cells or by
modulating hypermethylated GATA3 gene promoter in MDA-MB-231 cells. Moreover,
our data on DNMT inhibitor, 5-AZA, which is a nucleoside analogue of DNMT inhibitor
approved by FDA for the treatment of myelodysplastic syndrome, showed that GATA3
mRNA expression relative to RPL19 was increased significantly only in MDA-MB-231
cells at 1 μM of 5-AZA and

MCF-7 cells were found to be irresponsive to any

concentrations of 5-AZA (250-1000 nM) (Figure 8.2). Our data is similar to the study of
Pryzbylkowski P et.al 2008, which showed that treatment of MDA-MB-231 cells with 5AZA at 2.5 M, for 96h resulted in re-expression of ER mRNA content (Pryzbylkowski,
Obajimi, and Keen 2008). GATA3 expression in breast tumors highly correlated with the
expression of estrogen receptor alpha (ER1). The highest expression of GATA3 and
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ER1 is associated with the most favorable survival outcomes. Even though MCF-7 cells
were irresponsive to any concentrations of 5-AZA (250-1000 nM), from this study also
claimed that after treatment 5-AZA with MCF-7 cells resulted in decreased ER mRNA
expression due to decrease stability through altered subcellular localization of RNA
binding protein, HuR. Therefore, control of mRNA stability may involve (Pryzbylkowski,
Obajimi, and Keen 2008). As GATA3 gene in ER breast cancer cells (MDA-MB-231
cells) remained silent due to inappropriate promoter methylation (hypermethylation)
(Sun, Asmann, et al. 2011, Chou et al. 2013, Hoch et al. 1999, Yan et al. 2010, Yoon et
al. 2010), we predict that WYRE is able to reactivate GATA3 gene expression in MDAMB-231 cells by altering the methylation status of GATA3 promoters in a mechanism
which is probably different from 5-AZA (Peedicayil 2006). Before analyzing GATA3
promoter methylation at specific regions, we investigated the effects of WYRE on global
DNA methylation in these cell lines, because the genome of cancer cells displays global
hypomethylation in one hand, and local gene-specific hypermethylation on the other
(Sharma, Kelly, and Jones 2010). Global DNA methylation was determined as 5methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC). Although 5-mC is the
predominant epigenetic marker in mammalian genome, 5-hmC is a newly discovered
epigenetic modification that is presumably generated by oxidation of 5-mC by teneleven-translocation (TET) family of cytosine oxygenases (Chen et al. 2013). The
conventional bisulfite treatment is unable to differentiate 5-mC from 5-hmC, we
therefore used ELISA-based techniques (Cell Biolabs, San Diego, CA). In this method,
5-mC is detected as 5'-methyl-2'-deoxycytidine (5MedCyd) content of the genomic DNA.
Our data indicated a cell-line specific alteration in the global DNA methylation pattern in
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these two cell lines (Figure 10). In MCF-7 cells, 5-mC was found to increase
significantly by WYRE only in 50 µg/mL concentrations (Figure 10.1) which indicates a
possibility of hypermethylation but 5-hmC remained unaltered (Figure 10.2). On the
other hand, in MDA-MB-231 cells, 5-mC remained unaltered (Figure 10.1), but 5-hmC
reduced significantly in all of the concentrations of WYRE used in this study (Figure
10.2) indicating a probability of hypomethylation. Our data are to some extent identical
with the DNMT inhibitor DAC, which is, at 8 µM concentration, able to cause hypo
methylation in docetaxel-resistant MCF-7 and MDA-MB-231 cells after 24 h treatment
even though the data are significantly different only in MDA-MB-231 cells (Kastl, Brown,
and Schofield 2010). Although we are unable to explain the mechanism (s) properly,
because 5-hmC modifications are known to prevalent in DNA of embryonic stem cells
and neurons (Kriaucionis and Heintz 2009, Tahiliani et al. 2009) and 5-hmC contents
are reduced in the carcinomas of prostate, breast, liver, lung, pancreas, and colon
(Yang et al. 2013), our data indicate that WYRE like other DNMT inhibitors has the
potential to modulate global DNA methylation which is specific to the ER sensitivity
breast cancer cell lines. Moreover, these alterations in global DNA methylation in MCF-7
(5-mC) and MDA-MB-231 (5-hmC) cells by WYRE are enabling us to analyze DNMT
and TET enzymes at the message level.
DNMT family of enzymes catalyze the covalent addition of a methyl group at the carbon
5 position of a CpG dinucleotide (5-mC) into the genome (Haffner et al. 2011, Kudo et al.
2012) and TET family of enzymes oxidized 5-mC to 5-hmC (Chen et al. 2013, Tan and
Shi 2012, Hashimoto et al. 2012, He et al. 2011, Ito et al. 2011). In human genome,
five DNMT enzymes have been identified; among them two de novo methyltransferases
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(DNMT3A and DNMT3B) and the maintenance methyltransferase DNMT1 are the key
regulators of DNA methylation (Bestor 2000, Okano et al. 1999). Mammalian cells
express three TET genes, TET1, TET2, and TET3 (He et al. 2011) and TET family of
enzymes is capable of catalyzing the sequential oxidation of 5-mC to 5-hmC, 5formylcytosine (5-fC), and finally 5-carboxylcytosine (5-caC) (Bestor 2000, Kriaucionis
and Heintz 2009, Tahiliani et al. 2009, Ito et al. 2011). 5-caC can be recognized and
cleaved by thymine-DNA glycosylase that restore unmethylated cytosine via baseexcision repair (BER) system (Ito et al. 2011 ). Thus, active DNA demethylation may be
achieved through a multistep oxidation of 5-mC with the generation of various forms of
intermediates (Chen et al. 2013). Therefore, analyses of DNMT and TET enzymes are
necessary. It was observed that mRNA contents of DNMT1, 3A, and 3B were increased
in both cell lines in a concentration-dependent manner. The increase was significant in
MCF-7 cells treated with 50 µg/mL of WYRE whereas, a significant increase was
observed in MDA-MB-231 cells treated with 25 and 50 μg/mL of WYRE as compared to
controls (Figure 11). Moreover, TET mRNA analysis indicates that in MDA-MB-231 cells
treated with 50 μg/mL of WYRE, TET3 mRNA expression significantly enhanced (Figure
12). Although the specific reason of enhanced DNMT mRNAs in MDA-MB-231 cells by
WYRE is unknown to us, alteration in DNMT enzyme activity should be reflected on
specific gene methylation as well as in global DNA methylation. The present data also
showed that 5-hmC was dramatically reduced by WYRE in MDA-MB-231 cells (Figure
10.2) which may create a necessary stimulation to DNMT genes to become activate and
to synthesize DNMT mRNAs. Moreover, TET mRNA analysis indicates that MDA-MB231 cells treated with 50 µg/mL of WYRE compared with controls TET3 significantly
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increased. These data support that the reduced level of 5-hmC may increase TET3
mRNA to get the MDA-MB-231 cell ready for 5-hmC syntheses and further converted to
other intermediates. In contrast, in MCF-7 cells increased in 5-mC and no alteration in
5-hmC, made DNMT genes to become unresponsive to alter GATA3 promoter
methylation. However, in docetaxel-resistant MCF-7 and MDA-MB-231 cells, the DNMT
inhibitor DAC (8 M, 24 h) altered DNMT enzyme mRNA (DNMT1, 3A and 3B)
expression in a cell line specific manner; increase in MCF-7 cells and decrease in MDAMB-231 cells (Kastl, Brown, and Schofield 2010). Further studies related to DNMT and
TET proteins or enzymes would be required to understand the possible mechanism (s)
played by TET (or to explain these results).
As mentioned earlier, the genome of cancer cells displays global DNA hypomethylation
on one hand, but local gene-specific hypermethylation on the other(Sharma, Kelly, and
Jones 2010). As the expression of GATA3 mRNA is dependent on the methylation
status on the promoter, we therefore focused on GATA3 promoter at a specific locus by
applying RE techniques (Iida et al. 2006, Oakeley 1999). The amplified GATA3 fragment
is spanned 580 bp and consists of thirty-two 5'-CG-3' and six 5'-CCGG-3' sites. We
digested the genomic DNA with HpaII and Msp1 RE and amplified with GATA3 genespecific primers. The data were normalized against ACTB (Figure 13). Our data indicate
that in MCF-7 cells all six 5'-CCGG-3' sites in GATA3 promoter are methylated only at
inner C. Moreover, WYRE has no significant effect in altering methylation of either inner
or outer C in these regions. However, in MDA-MB-231 cells methylation of inner C
appears to be identical with MCF-7 cells (all methylated) but some MDA-MB-231 cells
the outer C methylation status seems to be different from MCF-7 cells. Treatment of
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WYRE (50 μg/mL) is able to demethylate outer C in 5'-CCGG-3' sites in these cells
suggesting the potential of WYRE to demethylate GATA3 gene promoter at specific
region.
Taken together, our data indicate that WYRE is able to inhibit both ER + and ER cell
viability in a concentration-dependent manner and activates GATA3 mRNA expression
with an alteration in global DNA methylation pattern. Although there could be other
mechanisms that can reduce cell viability, the response of ER- MDA-MB-231 cells to
WYRE is more pronounced than ER+ MCF-7 cells probably due to the difference in
methylation status of target genes among these two cell lines. GATA3 promoter analysis
at specific region is unable to demonstrate any dramatic demethylating effect of WYRE
at 5'-CCGG-3' sites with regard to inner C. Demethylation by WYRE in outer C or Cs in
other location of the promoter cannot be ruled out.
We next focused on compounds, which were isolated from WYRE (NCNPR No. 9800)
whether capable of selective upregulating GATA3 expression would demonstrate
anticancer activity, specially increased differentiation and decrease invasiveness. The
components of WYRE belonging to steroidal saponins and sapogenins are found to be
noncarcinogenic (2004). To our knowledge, fourteen steroidal saponins, two flavan-3-ol
glycosides and fourteen diarylheptanoids have been reported from wild yam (Figure 33,
34) (Ali, Smillie, and Khan 2013, Dong et al. 2007, Hayes et al. 2007, Sautour,
Miyamoto, and Lacaille-Dubois 2006, Yoon et al. 2010); among them diosgenin and
dioscin exhibits anticancer activity (Jagadeesan et al. 2012). Therefore, we employed
dioscin and diosgenin as anticancer agents in our further studies.
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Figure 33: Base peak chromatograms of the D. villosa (NCNPR #9800) extracts
analyzed using UHPLC-QToF-MS in positive ESI mode: dioscoreavilloside A (1),
dioscoreavilloside B (2), parvifloside (3), protodeltonin (4), protodioscin (5), protobioside
(6),

huangjiangsu

A (7),

pseudoprotodioscin

(8),

25(R)-dracaenoside

G

(9),

zingiberensis saponin I (10), deltonin (11), dioscin (12), progenin III (13), and diosgenin
(14) (Ali, Smillie, and Khan 2013)
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Figure 34: Structures of compounds isolated from WYRE (NCNPR#9800)(Ali, Smillie,
and Khan 2013)
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Our data showed that dioscin and diosgenin were able to reduce in vitro cell viability of
both ER+ (MCF-7) and ER (MDA-MB-231) human breast cancer cells (Figure 14). Also,
dioscin (IC50= 3.85 and 2.07 µM in MCF-7 and MDA-MB-231cells, respectively) is more
potent than diosgenin (IC50 > 24.13 and 20.10 µM in MCF-7 and MDA-MB-231cells,
respectively) in both cell lines (Figure 14). Moreover, our study has identified a key
mechanism for GATA3 induced inhibition of metastatic propensity of Basal TripleNegative Breast Cancer (BTNBC), an aggressive form of breast cancer with poor
prognosis. We have demonstrated that only dioscin at 5.76 µM could induce GATA3
mRNA expression in MDA-MB-231 cells (Figure 16). To validate the mRNA result, we
analyzed GATA3 protein expression by using a polyclonal antibody specific for GATA3
and our results showed that GATA3 protein level was enhanced in a concentrationdependent manner in MDA-MB-231 cells treated with dioscin 1.15-5.76 µM. We have
also used 5-AZA (a known demethylating agent) for comparison. Our data indictaed that
5-AZA at 1µM was able to increase GATA3 protein in MDA-MB-231 cells (Figure 17).
The expression of GATA3 protein in MCF-7 and MDA-MB-231 cells were studied by
visual fluorescence probe and observed under confocal microscope LSM 510 (Figure
18). Our data demonstrated that within control groups MCF-7 cells have higher GATA3
protein expression than MDA-MB-231 cells and dioscin enhanced the expression of
GATA3 protein in both cell lines. Because of this, some MDA-MB-231 cells after
treatment with dioscin at 5.76 µM altered their morphology from spindle- shaped tumor
cells to epithelium- like in MCF-7 cells. These two distinct phenotypes are keenly
associated with cell invasiveness and noninvasiveness, respectively. Our result is
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similar to previous studies which showed that MDA-MB-231 cells expressed ectopic
GATA3 when engineered with the full-length GATA3 gene by a retroviral infection
system. These cells resembled the expression pattern of MCF-7 cells and displayed an
epithelial phenotype identical to MCF-7 cells, being cuboidal-like and aggregated (Chu
et al. 2012, Yan et al. 2010) (Figure 18). From these results prompted us to analyze the
effect of dioscin on regulator and downstream gene of GATA3. ZFPM2 gene encodes
the Zinc Finger Protein ZFPM2 is a widely expressed member of the FOG family of
transcription factors (Holmes et al. 1999, Svensson et al. 1999). The family members
modulate the activity of GATA family proteins, which are important regulators in
mammals. It has been demonstrated that the protein can both activate and downregulate expression of GATA-target genes (Holmes et al. 1999, Svensson et al. 1999).
Our data found that dioscin at 5.76 µM increased the expression of ZFPM2 mRNA in
both cell lines (Figure 19). GATA3 as a transcription factor binds with high affinity to
consensus GATA or GATA-like motifs located in promoter region by which it
transactivates gene expression. The study of Yan et al, 2010 showed that GATA3
functions to up- regulate E-Cadherin expression through binding its motifs located in ECadherin promoter (Yan et al. 2010). Moreover, E- Cadherin is a tumor suppressor gene
(Semb and Christofori 1998), which is encoded by the CDH1 gene (Huntsman and
Caldas 1998).

Loss of E-cadherin function or expression has been implicated in

cancer progression and metastasis (Yan et al. 2010, Polyak and Weinberg 2009). Ecadherin downregulation decreases the strength of cellular adhesion within a tissue,
resulting in an increase in cellular motility. This in turn may allow cancer cells to cross
the basement membrane and invade surrounding tissues (Yan et al. 2010, Polyak and
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Weinberg 2009). Our data showed that dioscin could up regulated of E-Cadherin
mRNA expression at 5.76 µM in both cell lines (Figure 20). These results from both
regulator (ZFPM2) and downstream genes (CDH1) of GATA3 were correlation to GATA3
expression effect by dioscin. Moreover, cancer metastasis also requires migration of
cancer cells. During cell migration, pericellular proteolysis of extracellular matrix (ECM)
is important for cell protrusion. The proteolytic degradation of ECM mediated by
extracellular proteases such as Matrix Metallopeptidases (MMPs) is required for breast
cancer cells migration and invasion. Therefore, we next investigated the effect of dioscin
on Matrix Metallopeptidase 9 (MMP9) and Vimentin (VIM) in MDA-MB-231 cells. MMP
family are involved in the breakdown of ECM in both normal physiological processes,
such as embryonic development ,angiogenesis, bone development, wound healing, and
cell migration, and

in pathological processes, such as arthritis and metastasis

(Vandooren, Van den Steen, and Opdenakker 2013). MMP9 can be also involved in the
development of several human malignancies including breast cancer, as degradation of
collagen IV in basement membrane and ECM facilitates tumor progression such as
invasion, metastasis, and angiogenesis (Groblewska et al. 2012). Another biomarker
gene vimentin is a type III intermediate filament (IF) protein that is expressed
in mesenchymal cells.
mesenchymally-derived

Because of this, vimentin is often used as a marker of
cells

or

cells

undergoing

an epithelial-to-mesenchymal

transition (EMT) during both normal development and metastatic progression (Leader et
al. 1987, Ulirsch et al. 2013). Our data showed that dioscin suppressed MMP9 mRNA
expression only at concentration of 2.30 µM (Figure 21) but inhibited VIM mRNA
expression at 2.30 and 5.76 µM of dioscin in MDA-MB-231 cells (Figure 22) which is
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similar to a previous study that indicated the expression of GATA3 is positively related to
elevated E-cadherin, but decreased vimentin, N-cadherin and MMP-9, which suggests
that GATA3 may drive the invasive breast cancer cells to undergo the reversal of
epithelial-mesenchymal transition (Yan et al. 2010). Furthermore, we employed woundhealing assay, which is simple and inexpensive to determine if dioscin could inhibit
tumor cell migration in MDA-MB-231 cells. Our results demonstrated that dioscin had
inhibitory effect on migration of MDA-MB-231 cells in both concentration- and timedependent manner (Figure 24-29). We also used Boyden chambers with an 8 micron
polyethylene terephthalate (PET) membrane and detect the quantity of cell migration by
using fluorescein technique by following the instruction provided by manufacturer
(Trevigen, Gaithersburg, MD) in both MCF-7 and MDA-MB-231 cells. Our data showed
that MDA-MB-231 cells which are BTNBC had higher migration activity when compared
with MCF-7 cells which are ER+ and exhibit higher expression of GATA3 gene (Figure
30). There are many studies indicated that MDA-MB-231 cells are invasive breast
cancer cells due to low expression of GATA3; this correlated with a poorer outcome
related to high tumor grade (poorly differentiated or undifferentiated), larger tumor size,
and short disease –free survival. On the other hand MCF-7 cells which are ER+, GATA3
positive and early stage well differentiated (non invasive) breast cancer had a very
favorable prognosis. (Amatori et al. 2010, Kouros-Mehr et al. 2008, Kouros-Mehr et al.
2006, Ordway et al. 2007, Yan et al. 2010, Yoon et al. 2010). Moreover, to see the effect
of dioscin on cellular migration, we then treated MCF-7 and MDA-MB-231 cells with
various concentration of dioscin (1.15-5.76 µM) and our data demonstrated that not only
MDA-MB-231 cells had inhibitory effect on migration by dioscin at 5.76 µM, but also
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MCF-7 treated with 5.76 µM of dioscin suppressed cell migration (Figure 31). We also
employed the same experiment but coated PEP membrane with BME for cell invasion
study. Our results showed that dioscin at 5.76 µM had similar effect on cell invasion and
cell migration in both cell lines. Moreover, treatment of dioscin at 5.76 µM inhibited 65%
and 60% of cell invasion in MDA-MB-231 and MCF-7 cells, respectively (Figure 32).
This result showed that MDA-MB-231 cells treated with dioscin at the same
concentration had a little higher effect of inhibited invasion than MCF-7 cells. Our data
indicated that dioscin markly inhibited migration and invasion in both breast cancer cell
lines. Importantly, increasing GATA3 expression in low expression MDA-MB-231 breast
cancer cells led to cancer cells differentiating and decreased their invasion potential
could be more advantage in women who have BTNBC that present very unfavorable
prognosis.

97

CHAPTER 5.

CONCLUSIONS

We concluded that WYRE alter DNA methylation pattern on the promoter region
of GATA3 gene showing demethylating activity of GATA3 gene in MDA-MB-231 cells.
We also demonstrated the inhibitory effect of dioscin, which isolated from WYRE on
proliferation, migration and invasion of MDA-MB-231 cells. Thus, dioscin could be a
potential agent that suppressed breast cancer metastasis in BTNBC via up regulating
GATA3 and E-Cadherin but inhibiting MMP9 and Vimentin. Moreover, investigating the
therapeutic potential and pharmacodynamic property of dioscin In vivo is imperative.
These findings reveal a new therapeutic potential for dioscin on anti-metastatic therapy
and in future this compound may be able to offer an efficacious adjuvant therapy to
women with breast cancer.
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International Conference on the Science of Botanicals (ICSB), meeting on April 15th -19th
, 2013 in Oxford, MS
2013 Travel Support Award from Society of Toxicology (SOT) to attend the Society of
Toxicology 52nd Annual Meeting in San Antonio, TX March 10-14, 2013
2013 Student Travel Award from the University of Mississippi to attend the Society of
Toxicology 52nd Annual Meeting in San Antonio, TX March 10-14, 2013
2012 1st prize poster presentation award in the Poster competition held at The 30th
South Central Regional Chapter Society of Toxicology (SCCSOT) meeting on
November 1-2, 2012 in Little Rock, AR
2012 3rd prize poster presentation award in the Poster Competition held at the
annual ACS Awards Ole Miss Local Section meeting on November 8th, 2012 in Oxford,
MS
2012 3rd Prize poster presentation award in The Poster Competition held at the 11st
International Conference on the Science of Botanicals (ICSB), meeting on April 12-15,
2012 in Oxford, MS

Society -------------------------------------------------------------------------------------------------------------------------Member of Society of Toxicology
Member of South Central Regional Chapter Society of Toxicology
Member of Society of Neuroscience
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